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ABSTRACT 
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Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal motor 
system disease that affects motoneurons causing paralysis and muscular 
atrophy. Recently, it has been discovered that defects in the protein TDP-
43 were present in most patients that suffer from ALS. Similar 
modifications in the Drosophila melanogaster conserved protein TBPH 
reproduced the motor symptoms observed in ALS patients, such as 
locomotion problems and reduced life expectancy. These phenotypes 
were mainly originated from alterations in the organization of proteins 
responsible for synaptic transmission at the neuromuscular junctions 
(NMJs) in Drosophila. 
The objectives of this work are to discover the proteins affected by TBPH 
function and determine their role in neuronal and non-neuronal tissues. 
Moreover, I would like to know how they exert their functions and 
establish whether these pathways are conserved in humans and/or 
modified in ALS patients. For these experiments, we took advantage of a 
genome wide proteomic screening to discover that Glutamic Acid 
Decarboxylase 1 (GAD1), the enzyme that converts Glutamate to GABA, 
was downregulated in flies lacking the expression of TBPH. We found 
that this alteration provoked the excessive accumulation of Glutamate, 
which in turn, promoted defects in the organization of the post-synaptic 
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proteins Disc Large and GluRIIA. Pharmacological treatments with 
Glutamate receptor antagonist Memantine was able to recover the 
motility problems described in TBPH null larvae including the clustering 
of the GluRIIA at the terminal membranes. Importantly, we discovered 
that the suppression of TDP-43 provoked the downregulation of GAD67, 
the GAD1 homolog protein in human neuroblastoma cell lines and 
analogous modifications were observed in iPSC-derived motoneurons 
from ALS patients carrying mutations in TDP-43, uncovering conserved 
disease mechanisms. In conclusion, we show for the first time a 
connection between Glutamate metabolism disorders and TDP-43 
proteinopathy, two pathological mechanisms of primary importance in 
ALS.  
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Initial remarks 
“The diagnosis as well as the anatomy and physiology of the condition 
amyotrophic lateral sclerosis is one of the most completely understood 
conditions in the realm of clinical neurology”. When Jean-Martin Charcot 
(1825-1893) said it in 1887, in his comments about “la sclérose 
amyotrophique”, he could not have been more wrong1. 
Charcot, by many regarded the father of neurology, has enormously 
contributed to medicine and to medical literature. His lectures have been 
translated in many countries and are an essential tool of any 
neurologist’s library2. A well-trained pathologist, with great eye to couple 
clinical observations (signs and symptoms) with anatomical evidence 
derived from autopsy3, he correlated chronic progressive paralysis and 
contractures observed in patients, to lesions within the lateral column 
and the anterior horn of the spinal cord2 (1865-1869). In 1874 he named 
“Sclérose Laterale Amyotrophique” for the first time4. Although he was 
not the first to discover ALS, as many predecessors of his had observed 
the disease in years previous to him, he was the first one in naming it and 
separating it from other neurological disorders1. Despite recent 
molecular and genetic discoveries have completely shaped our 
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understanding of ALS, many of his original clinical and pathological 
descriptions have remained virtually unaltered1. 
Granting Charcot with all the credentials, he failed to recognize ALS 
heterogenous nature and the overlapping with many other 
neuropathies5. Charcot observations were based on thorough clinical 
and pathological analysis, marvellous for the time, but insufficient to fully 
understand the complexity of the disease. Yet, he was not the only one 
to fall into this trap. Too many times in recent history, discoveries had 
led to the impression that ALS was a monogenic, homogeneous disorder. 
It is enough to mention the identification of the link between Superoxide 
Dismutase 1 (SOD1) and ALS, that inspired great excitement some 20 
years ago, yet this enthusiasm now seems unjustified1. As Turner has 
correctly stated in 1, “The history of ALS is beset by misunderstandings 
and false beliefs. From its 19th century beginnings, the path ahead has 
too often been considered straightforward”. Only today, thanks to 
advances in molecular biology and genetics, after the identification of 
dozens of genes correlated to ALS6, that we are able to understand the 
real complexity of this disorder.  
 
 
28 
 
1) ALS overview  
1.1) Clinical features of ALS 
 
ALS is a progressive and fatal neurodegenerative disease of the human 
motor system6. It affects principally lower (LMN) and upper (UMN) 
motoneurons in the cerebral cortex, brain stem and spinal cord7. The 
impaired synaptic transmission caused by the loss of these neurons 
induces paralysis of voluntary and involuntary movements and 
subsequent muscular atrophy. 
Although the signs and symptoms are of very variable nature, the clinical 
hallmark of ALS consists usually of a combination of LMN and UMN 
degeneration. Pure LMN (Progressive Muscular Atrophy – PMA) or UMN 
(Primary Lateral Sclerosis – PLS) are also possible, although rare. These, 
limb-onset manifestations, account for 70% of ALS epidemiology. In 25% 
of cases, bulbar-onset disease is observed, represented by speech and 
swallowing difficulties. Finally, 5% of patients suffer from respiratory 
problems at the onset6. 
UMN deterioration leads to spasticity, weakness, tendon reflexes and 
emotional lability. LMN loss, include fasciculation, wasting, and 
weakness. In most cases, the disorder begins in the arms and legs with 
symptoms that include foot drop, problems or inability to walk, loss of 
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complex hand movements or inability to lift heavier objects8. As the 
disease progresses, the patients become dependent on caregivers. In 
bulbar onset disease, symptoms include difficult or unclear articulation 
of speech due to muscle impairment (dysarthria), difficulty or discomfort 
in swallowing (dysphagia), hypersalivation (sialorrhea), malnutrition8. 
Tongue fasciculation is usually present. Axial decade causes head to drop 
and excessive outward curvature of the spine (kyphosis), pain and poor 
balance. Sphincter function is often spared, as are sensory functions and 
eye movement, the former preserved till the last stages8.  
Cognitive impairment was overlooked in the past. Today, however, it is 
believed that some 50% of ALS patients develop impaired 
neuropsychological functions9. It often reflects a progressive inability to 
understand or produce speech (dysphasia and aphasia) combined with a 
progressive loss of verbal and non-verbal semantic memory (semantic 
dementia)10. These cognitive modification affect “executive function, 
language, judgment, personality and behaviour” as explained in 10, and 
are associated with reduced survival. 
Pain can be present and intense if sensory neurons are involved. 
Headaches occur quite often. Early respiratory problems give rise to 
30 
 
breath shortening, also at rest in advanced stages that can significantly 
reduce the quality of life.  
The disease can induce depression and anxiety resulting in sleep 
deprivation and appetite loss11. Interestingly, some ALS patients take the 
situation philosophically, lowering the emotional burden in those 
occasions12. 
Clinical records report respiratory failure as the primary cause of death 
followed by pulmonary embolism and heart failure as secondary and 
rare13 consequences. Studies suggest also that deaths are often related 
to hypertension and malnutrition13. A more recent study14, performed on 
a cohort of 100 post-mortem ALS patients, summarized the principal 
causes of death and is shown in figure 114. 
 
Fig. 1) ALS patients cause of death. The figure shows that aspiration and bronhco-pneumonia 
account for more than 70% of total deaths in ALS patients. It also suggest that spinal onset is 
predominant in ALS (figure taken from 14). 
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1.2) Epidemiology of ALS 
 
The incidence of ALS is 2-3 people per 100,000 individuals per year and 
more frequent in men than in women15. The overall lifetime risk of ALS is 
1:400 in women and 1:350 in men. Higher prevalence is seen in some 
countries in comparison to others, indicating that geographical position 
plays a role16.  
Statistically, the onset of the disease is between 58 to 63 years of age for 
the sporadic forms and 47 to 52 for the familial ones17. Relentless 
thereafter, half of the patients die within 3 years from the first symptoms 
while  another 20% within 5 to 10 years17. Early respiratory problems and 
bulbar involvement were associated with reduced survival17.  
 
1.3) Diagnosis and treatment of ALS 
 
The more we know about ALS, the more we understand the need to 
formulate dynamic and evolving consensus guidelines for clinical 
diagnosis18. The first such guidelines were developed in 199419, by “The 
Consortium on Clinical Trials in ALS”, that met in Airlee, Warrenton, 
Virginia. This group of people included clinical practitioners, Food and 
Drug Administration (FDA) officials, pharmaceutical companies’ 
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representatives and patients’ lawyers that met with the aim of creating 
a document that could provide a common groundwork for ALS diagnosis, 
useful to conduct clinical trials on an inclusion/exclusion base, easy 
accessible for health care systems at a global level. The result of this 
meeting was the “El Escorial Criteria”20. Revised many times since then, 
the document is intended “to improve the efficiency and consistency of 
trial analysis and design” and “facilitate the admission into clinical trial” 
sooner during the course of the disease. It also deals with ethics, 
patient’s interests, statistical analysis approach, survival measures and 
more19. The El Escorial Criteria for diagnosis can be found on the World 
Federation of Neurology Research Group for Motoneuron Disease 
website (http://www.wfnals.org). The most updated version of the 
document21 states that “ALS diagnosis is based on the exclusion of 
alternative causes of signs and symptoms outlined in the original 
diagnostic criteria” and “requires clinical progression”. It needs, 
furthermore, the presence of at least one of the following 
manifestations: 
- progressive UMN or LMN in at least one limb or region of the body; 
- LMN deficiency evidenced by clinical examination in one body 
region and/or Electromyography (EMG) (in the form of neurogenic 
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potentials, fibrillation potentials, positive sharp waves and 
fasciculation potentials) in at least two body regions. 
Based on the extensive data gathered in clinical trials, potential ALS 
patients are categorized in suspected, possible, laboratory-supported 
probable, probable and definite21. Thanks to a very limited number of 
false positive diagnosis in support of the El Escorial Criteria, admission 
for clinical trial is currently granted to all patients ranging from possible 
to definite21.  As Agosta has stated in 22, “It is difficult to conceive of a 
less stringent criterion that would still ensure that patients are 
appropriately diagnosed”. Consistently, a broader LMN involvement to 
more than one body region can be sufficient to meet the criteria for ALS 
diagnosis, even in the absence of UMN signs and symptoms21, ensuring 
faster clinical enrolment for patients with restricted phenotype. 
Interestingly, even if not conceived as a staging system, the El Escorial 
serves very nicely in establishing the disease prognosis based on the 
initial diagnosis. In this sense, patients diagnosed with definitive ALS 
have reduced survival rates in comparison to patients diagnosed with 
possible ALS23. It is believed that ultimately, after many revisions, it 
seems that the El Escorial meets the present needs for a successful ALS 
diagnosis22. It must be said, however, that there are many issues still to 
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be addressed, overlooked by these criteria, such as the heterogeneity of 
ALS phenotypes and the genetic component involved22, but in the 
absence of clear biomarkers for disease diagnosis and progression, The 
El Escorial Criteria represent a valid tool for ALS identification.  
Currently, ALS is managed by treatment of symptoms and pain relief24. 
This is because it is effective, in the sense that it is correlated with longer 
life expectancy, especially for patients with moderate disease 
penetration that attend specialized and multidisciplinary ALS clinics24. In 
such institutions, patients receive “comprehensive care from a physician, 
physical therapist, occupational therapist, speech pathologist, dietitian, 
social worker, respiratory therapist, and nurse case manager”, as Miller 
suggests in 24. Symptomatic and palliative care, such as percutaneous 
endoscopic gastrostomy and non-invasive ventilation25, are usually 
combined with Riluzole, an inhibitor of Glutamate release, the only FDA 
approved drug for ALS treatment, that prolongs survival from 3 to 6 
months26. Many drugs are currently being tested, some of them are 
summarized in 27. Still, despite intensive academic and industry efforts, 
it has been more than 20 years since Riluzole was first approved, and 
currently it is the only available drug for treatment. Reason for this lack 
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of success is partly the obscurity of the mechanisms that are behind ALS 
pathogenicity. 
 
1.4) Genetic and environmental factors contributing to ALS 
 
Let’s talk about the genetics first: it is important to understand that in 
the past and present, scientists have encountered difficulties in 
correlating the disease with a specific set of genes. Familial ALS (fALS), 
where familial stands for a condition that is hereditary, accounts only for 
10% of epidemiology28; so far, the scientific community has identified a 
dozen of loci that might be responsible for disease onset6. Most of the 
research in ALS is based on the characterization of these genes. However, 
often the same mutations can induce completely different clinical 
phenotypes, making the understanding of the disease even more 
complicated29. In the remaining 90% of ALS patients, no obvious genetic 
correlation has been found, thus referred to as sporadic ALS (sALS).  
As it was mentioned at the very beginning, the identification of SOD1 
mutations in fALS back in 199330 had inspired great excitement. It is 
considered that some 20% of fALS is correlated to SOD1 mutations (some 
150 mutations identified to be pathogenic so far). The mutant form of 
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the protein escapes regulatory processes, aggregates and forms 
intracellular inclusions which interfere with cellular metabolism31.  It 
furthermore lacks its natural ability to remove free radicals, which 
accumulate in the cell. Some 15 years later, SOD1 was shown to 
aggregate in ALS patients even in the absence of mutations32. Is SOD1 a 
cause or a consequence of ALS?33 Similarly to SOD1, other mutant 
proteins have been discovered: UBQLN2, OPTN, SQSTM1, VCP and many 
others, suggesting that ALS is a proteinopathy31. Most certainly, 
however, one of the most important breakthroughs in the field of ALS 
was achieved with the identification of Transactive Response DNA 
Binding Protein of 43 kDa (TDP-43) protein pathology. Mutations inside 
TDP-43 gene (TARDBP) account for 5% of fALS. Independently of whether 
TARDBP gene is mutated or not, the vast majority (up to 90%) of ALS 
patients suffer from the neuronal aggregation of TDP-43 inside ubiquitin 
positive cytosolic inclusion. TDP-43, reviewed in depth later in this thesis, 
is a heterogeneous ribonucleoprotein located normally in the nucleus 
where it harbours many important cellular functions, primarily as RNA 
splicing factor. During stress, TDP-43 naturally shifts from the nucleus to 
the cytoplasm where it aggregates in stress granules through its prion 
like domain34. In ALS, however, it seems that TDP-43 is unable to leave 
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these structures and relocate to the nucleus. It is still a matter of debate 
whether it is the lack of TDP-43 function from the nucleus or the 
formation of TDP-43 cytosolic aggregates that causes the severe 
neurodegeneration described in ALS35. Besides TDP-43, there are others 
RNA binding proteins, such as FUS, TAF15, EWSR1, believed to contribute 
to ALS6.  
In parallel to this notion, in 201136 a study claimed that approximately 
40% of fALS patients have an expansion of GGGGCC hexanucleotides 
(G4C2) repeats  between two exons in the 5’ non-coding region of 
C9ORF72, a gene of unknown function36. It is estimated that the affected 
individuals present hundreds or even thousands of (G4C2) repeats. In this 
direction, in situ hybridization studies have shown that there is an 
accumulation of RNA particles in the frontal cortex and spinal cord of ALS 
patients affected by C9ORF72 hexanucleotide repeats. It is believed that 
the RNA transcribed from this abnormally repeated gene are able to form 
RNA foci acquiring a toxic function by sequestrating healthy RNAs and or 
associated ribonucleoproteins36.  
Apart from the genetic origin of the disease, some studies suggested that 
ALS might begin consequently to the exposure to toxins of various nature 
present in the environment37. Agricultural substances and nutrition, 
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electro-magnetic fields, heavy metals, industrial dust or harmful vapours 
had been correlated with the onset of the disease. Smoking, for example, 
is believed to increase the probability of developing ALS, especially for 
those who start young37. Similarly, many patients have declared of 
having been exposed to agricultural harmful substances. Some of these 
are pesticides, fertilizers, herbicides, insecticides, and formaldehyde, the 
last believed to increase by two folds the risk of ALS37. In another study, 
low frequency radiation was proven to increase free radicals 
accumulation through oxidative stress38 and was correlated with ALS. On 
the completely opposite direction, studies have shown that ALS is 
associated with increased physical activity39, since many ALS diagnosed 
patient happened to be former athletes. Incongruent results were 
obtained in this matter, so this correlation has yet to be determined. 
Another study states that consumption of food rich in Glutamate can 
have a role in the development of the disease suggesting that increased 
Glutamate activity may lead to neuronal death40. It was also reported 
that the intake of Omega 3, Vitamin E and high-fiber food may have a 
protective effect41. 
However, since most of the evidences described above came from 
questionnaires that are subject to bias42, until proper biomarkers were 
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available, it is difficult to assess the role played by environmental factors 
in ALS. 
 
1.5) Molecular mechanism in ALS 
 
One of the most obvious molecular mechanism disorders in ALS is related 
to Glutamate excitotoxicity: high levels of Glutamate - the most 
important excitatory neurotransmitter in the human brain - were 
detected in patients with ALS43. A reason for this could reside in the 
apparent downregulation of the Glutamate transporter EAAT43, that 
normally removes  the excess of Glutamate from the synaptic cleft. The 
excesses of Glutamate activates its own receptors (Glutamate 
Receptors), producing over-firing and neuronal degeneration, a 
phenomenon referred to as excitotoxicity44.  
Mitochondria are also subject of intense research in ALS45. These 
organelles have essential functions in cell respiration, energy production, 
calcium metabolism and apoptosis. It seems that in ALS the mitochondria 
are severely affected both biochemically and morphologically46. These 
modification are found in different tissues of ALS patients such as skeletal 
muscles, liver and/or motoneurons47. Interestingly, SOD1 mutant 
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proteins were found in aggregates at the outer membrane of the 
mitochondria in ALS patients48. The accumulation of misfolded SOD1 
interferes with the processes responsible for ATP and energy production 
and impairs mitochondrial calcium buffering capabilities, triggers 
apoptosis and disrupt the axonal transport of this organelle49. 
Mitochondrial deficits affect also the transport of cellular proteins, lipids 
and RNA molecules50 leading to further accumulation of these 
macromolecules in the degenerating motoneurons50. Additionally, 
biopsies performed in post-mortem ALS tissues have revealed the 
activation of oxidative stress in response to the formation of free 
radicals51. Similar evidences were obtained from patients cerebrospinal 
fluids, serum and urine51. Elucidating the molecular mechanisms 
underlying the pathological modifications described before is critical to 
uncover the molecular targets of the disease and will also help to develop 
efficient drugs aimed to prevent and treat ALS51.  
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2) Transactive response DNA binding protein 43 kDa (TDP-43) 
2.1) TDP-43, metabolic overview 
During degeneration, neuronal cells suffer the aggregation of cytosolic 
proteins and ALS is not an exception. In 2006, Neumann and colleagues34 
discovered that TDP-43 was the most abundant protein present in the 
cytosolic aggregates formed in the brains of ALS patients (Fig. 2). 
Moreover, Neumann showed that TDP-43 appeared abnormally 
modified harbouring several posttranslational modifications such as 
ubiquitination, hyper-phosphorylation and cleavage of its C-terminal 
(Fig. 2). TDP-43 is a 43 kDa protein discovered in 1995 by Ou and 
colleagues52. It was initially linked to HIV infection because of its capacity 
to bind the TAR DNA sequences of this virus (from which TDP-43 derives 
the name).  
TDP-43 is encoded by TARDBP gene. It localizes predominantly in the cell 
nucleus and is ubiquitously expressed in almost all the tissues. The 
molecular structure of this 414 amino acids long RNA binding protein 
comprises two RNA recognition motifs (RRM1 and RRM2) in the N-
terminal part and a Glycine rich domain in the C-terminal34. Also, a 
nuclear localization sequence (NLS) and a nuclear export signal (NES) are 
both found in the N-terminal (Fig. 3). 
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Fig. 2) TDP-43 is misregulated in motoneurons of ALS patients. On the left: 
Immunohistochemistry of brains derived from FTLD patients shows that TDP-43 is devoided 
from the nuclei and aggregated in cytosolic inclusion of affected neurons. On the right: 
biochemical analysis of FTLD brains reveals that TDP-43 is ubiquitinated, hyper-
phosphorylated and truncated in C-terminal fragments (figure taken from 36).  
 
 
Fig. 3) Schematic representation of TDP-43 protein structure. The N-terminal of TDP-43 
harbours the two RRM and the NLS/NES sequences. The C-Terminal is rich in Glycine and 
serves for protein-protein interactions. The total length of the protein is 414 amino acids.  
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2.2) TDP-43 gene and its expression 
 
TARDBP gene is well conserved across species53 presenting  a high degree 
of similarity between human, mice, Drosophila melanogaster and 
Caenorhabditis elegans53. In humans, TDP-43 is located on the first 
chromosome at position 1p36.21 and the genomic sequence is 
constituted by six exons and five introns53 that generate, at least, 10 
different TDP-43 isoforms after alternative splicing53. Interestingly, the 
close examination of the databases revealed that in the mice and human 
genome there are multiple sequences with high homology to TARDBP, 
some with as much as 90% similarity. These sequences derive, most 
probably, from retrotransposition events that involved TDP-43 mRNA53. 
Regarding TDP-43 protein expression patterns, it is ubiquitously 
expressed52 in many different tissues including brain, heart, spleen, 
ovary, placenta, pancreas, testis, lung and kidney54.  
 
2.3) TDP-43 protein structure and interactome 
 
The first time TDP-43 was attributed the role of RNA binding protein was 
in 2001, when Buratti et al54 described TDP-43 regulation of the splicing 
of the human cystic fibrosis transmembrane conductor regulator (CFTR) 
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pre-mRNA. More specifically, Buratti showed that TDP-43 RRM1 domain 
bounded with high affinity the TG di-nucleotidic stretches ((TG)m(T)n) 
present on the exon 8 – exon 9 boundary of the CTFR pre-mRNA, allowing 
for exon 9 skipping. Here, the phenylalanine 147 and 149 were 
fundamentally important for TDP-43 - CTFR interaction. In contrast, the 
RRM2 domain did not show to be similarly important, suggesting that the 
RRM1 domain is sufficient to binding RNA. A multitude of RNA molecules 
were later shown to be regulated by TDP-43. In contrast, the Glycine rich 
C-terminal serves as the docking domain for protein-protein interactions. 
Studies demonstrated that TDP-43 was able to interact with many other 
proteins, primarily heterogeneous ribonucleoproteins (hnRNP), such as 
hnRNP A2/B1, hnRNP A1, hnRNP C1/C2 and hnRNP A3. 
According to Krecic et al55, the presence of the two RNA binding domains 
(RBDs) at the N-terminal part and the Glycine rich region in the C-
terminal portion, classifies TDP-43 as an RNA binding protein (RBP) that 
belongs to the group of hnRNPs.  
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2.4) TDP-43 function and localization 
 
The best characterized role of TDP-43 is certainly related to RNA splicing 
through UG repeats binding56. However, the regulation of intronic 3’- 
untranslated regions (3’-UTR) and non-coding regions of long transcripts 
were also described62. High throughput sequencing of CLIP RNA 
derivatives showed that TDP-43 was able to bind more than 6000 RNA 
sequences57, suggesting the functional importance of this protein. This 
last study also revealed that the great majority of these transcripts were 
related to synaptic activity or neuronal development including human 
CFTR54, apolipoprotein 258, serine/arginine-rich splicing factor 259. TDP-
43 also affects the RNA turnover of cyclin-dependent kinase 659, histone 
deacetylase 660, Futsch (the Drosophila homologue of microtubule-
associated protein 1B (MAP1B))61 and low molecular weight 
neurofilament protein62. 
In normal conditions, TDP-43 localizes in the euchromatin zones of the 
nucleus, primarily in the perichromatin fibrils and nuclear speckles where 
transcription and splicing occur. The intracellular localization of TDP-43 
is mediated by the NLS, localized before the two RRM domains and the 
NES, present inside the RRM2 domain, just before the Glycine rich 
region. However, it is possible to detect the presence of TDP-43 within 
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the cytoplasm in both normal and stressed cells63. The cytoplasmic 
localization of TDP-43 relates to the transport of RNA granules and to the 
synthesis of factors involved in neuronal plasticity64. Under stress 
conditions, TDP-43 redistributes from the nucleus to the cytoplasm 
where it forms part of the stress granules. These structures are able to 
sequester redundant mRNAs and promote neuronal survival65. It is also 
believed that TDP-43 is involved in the biogenesis and maturation of 
microRNA (miRNA) through the direct interaction with Drosha 
complex66. Moreover, TDP-43 may also behave as a negative 
transcription factor as described in the regulation of HIV DNA52. Finally, 
as described for different RNA binding proteins, TDP-43 is capable to 
regulate its own mRNA expression levels by interacting with specific 
sequences present at the 3’-UTR region of TDP-43 mRNA67.  
In conclusion, TDP-43 performs many cellular functions, primarily related 
to RNA biology (Fig. 4) and, therefore, it is not surprising that defects in 
TDP-43 metabolism lead to disease states. 
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Fig. 4) TDP-43 has many important cellular functions. In the nucleus TDP-43 acts primarily in 
pre-mRNA splicing, miRNA processing and transcriptional regulation. Many of this functions 
are achieved through interactions with hnRNPs. In addition, TDP-43 is involved in mRNA 
transport from the nucleus to the cytoplasm, mRNA stability and stress granule formation. 
TDP-43 is also able to auto-regulate its own expression by regulating TDP-43 mRNA (figure 
taken from 68). 
 
2.5) Role of TDP-43 in neurodegeneration  
The existence of ubiquitin positive cytosolic inclusions in post-mortem 
brains of individuals with ALS and FTLD was first described by by Leigh et 
al69 and Okamoto et al70 in 1991 and 1992 respectively. However, it was 
Neumann et al34 in 2006 who identified that TDP-43 was the major 
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protein present inside these abnormally formed intracellular 
inclusions34. Immunostaining analysis performed utilizing specific 
antibodies raised against TDP-43 (Fig. 5) indicated that this protein was 
absent from the nuclei of degenerated neurons and relocated inside the 
characteristic ubiquitin positive inclusions suggesting that TDP-43 “may 
redistribute from nucleus to the cytoplasm in affected neurons”. 
Additional observations demonstrated that TDP-43 appeared hyper-
phosphorylated and ubiquitinted in affected brains. In addition, the 
protein seemed abnormally cleaved at its C-terminal part generating 
multiple degradation products. Similar modifications were observed in 
samples obtained from patients with sporadic forms of ALS. 
After Neumann’s study, the number of publications regarding TDP-43 
raised dramatically (2086 hits on TDP-43 from 2006 to 2017 in 
comparison to 12 hits from 1995 to 2006) suggesting the rise in interest 
of this protein related to neurodegeneration. In agreement with this 
view, independent research conducted by Arai et al71 identified TDP-43 
as the main component of the ubiquitin positive inclusions present in 
neurons and glia sited in the temporal, frontal and parietal cortex of 
patients suffering of FTLD and ALS. Other anatomical areas like the 
hippocampus, the brain stem and the cerebellum were similarly 
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modified. Similar modifications in TDP-43 - ubiquitin positive and tau 
negative cellular aggregates - were also described in the cytoplasm and 
inside the neurites of the temporal cortex, hippocampus and caudate 
nuclei. Spinal cord motoneurons of FTLD patients with MND and ALS 
presented analogous modification in TDP-43.  
Regarding the morphology of TDP-43 inclusions, the authors stated: 
“TDP-43 stained curved or bullet-shaped inclusions in the cytoplasm of 
glial cells in the grey matter, and anterior and lateral funiculi of lumbar 
spinal corda in all the ALS and FTLD-MND cases”. An interesting 
observation is that Arai et al., study was sent to the journal revision 4 
days before Neumann et al., paper was published on the 6th of October 
2006, indicating that the two groups were conducting in parallel almost 
identical studies. Therefore, in my view, it is important to recognize Arai’s 
work as equally pioneering as Neumann’s, even if the latter is usually 
regarded as the discoverer of TDP-43 pathology in FTLD and ALS. 
Moreover, Arai’s work seems to be more complete in certain segments, 
such as the characterization of TDP-43 localization in different regions of 
the brain and spinal cord. 
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Fig. 5) TDP-43 immunoreactivity in FTLD post-mortem brains. Above: immunofluorescence 
studies show that TDP-43 co-localized with ubiquitin positive cytosolic inclusions in neurons 
derived from FTLD patients. The aggregates can either have a round or skein-like shape. 
Below: immunohistochemistry studies taken from ALS patients brain regions (hippocampus, 
frontal and temporal cortex) and at different magnifications confirm that TDP-43 pathology 
is widespread in FTLD brains (figure taken from 34). 
In 2007 Neumann et al72, characterized the pathological aggregation of 
TDP-43 in the white matter of FTLD patients. The biochemical signature 
was the same as in the grey matter of FTLD and ALS patients, thus hyper-
phosphorylated, ubiquitinated and cleaved in many degradation 
products. In addition, it was discovered that the cytoplasm of glial cells, 
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most probably oligodendrocytes, was also susceptible to TDP-43 
aggregation. Here the abundance and the shape of the inclusions varied 
significantly, being rounded, comma-shaped and in certain cases 
extended inside cytoplasmic processes. TDP-43 aggregates in the glia 
(astrocytes and microglia) were not ubiquitinated and perhaps more 
importantly, the glial inclusions of TDP-43 in the medulla and spinal cord 
were found in concomitance with neuronal inclusions in the same 
regions.  
Ahead of the demonstrations regarding the role of TDP-43 in FTLD and 
ALS, Mackenzie et al73, suggested that this was not always the case. On a 
large cohort of post-mortem ALS brains, which included fALS with and 
without SOD1 mutations, sALS and ALS with dementia, the group found 
that TDP-43 inclusions were negative in patients carrying SOD1 
mutations. Thus, in these individuals TDP-43 retained its normal nuclear 
localization without suffering pathological modifications. These 
observations were confirmed in the transgenic mouse G85R SOD1, 
considered to be one of the best experimental models to study ALS since 
1993, indicating that the disease may arise from TDP-43 independent 
molecular pathways. In agreement with this idea, Amador-Ortiz et al74, 
discovered TDP-43 ubiquitin positive cytosolic inclusions in patients 
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suffering of Hippocampal Sclerosis (HpSCL) and Alzheimer disease (AD). 
These studies showed that 78% and 20% of the HpSCL and AD patients 
respectively presented abnormal modification of TDP-43 with protein 
inclusions localized in the dentate fascia of the hippocampus and inside 
the entorhinal cortex. In some cases, the occipitotemporal lobe and the 
inferior temporal gyri were affected. In AD cases, the inclusions were 
found around the amygdala. Interestingly, this group analysed the shape 
of the TDP-43 positive inclusions by electron microscopy and observed 
that TDP-43 in FTLD and AD had mainly a granular and filamentous 
pattern in the cytoplasm and neuritic processes. In support to this, 
Higashi et al75 observed TDP-43 positive inclusions in the amygdala, 
hippocampus, and dentate gyrus of patients with AD (33%). The glial and 
the upper layers of the cerebral cortices in these patients were also 
immunoreactive for TDP-43 inclusions. In addition, this group described 
TDP-43 inclusions in the cases of dementia with Lewy Bodies (DLB) (45% 
of the cases) distributed in the amygdala, hippocampus, dentate gyrus, 
entorhinal, occipitotemporal and inferior temporal cortices. 
In summary, defects in TDP-43 metabolism has become an important 
research focus in neurodegeneration from 2006 onwards and TDP-43 
cytosolic inclusions were documented in the brain of several neural 
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disorders such as ALS, FTLD, DLB and AD. Because of its recurrence, TDP-
43 cytosolic inclusions seem to represent a valid marker for disease 
diagnosis and possibly treatment. However, we still do not know why in 
some ALS cases TDP-43 does not exhibit this pathological state, 
indicating the involvement of different molecular pathways. This is 
obvious in the case of SOD1-ALS mice model. Moreover, the presence of 
TDP-43 pathology in apparently different neuronal diseases suggests 
that TDP-43 may not be specific for ALS and FTLD and/or rather 
represents the consequence of a previously established 
neurodegenerative processes.  
At this point, it comes naturally to redirect to Charcot’s statement at the 
beginning of this thesis: “The diagnosis as well as the anatomy and 
physiology of the condition amyotrophic lateral sclerosis is one of the 
most completely understood conditions in the realm of clinical 
neurology”.   
Today, the best we can say is that until the molecular mechanisms of ALS 
are not fully elucidated, every assumption should be given very carefully.  
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3) Glutamate-GABA metabolism 
3.1) Glutamic acid metabolism 
 
The Glutamic acid is a ubiquitous non-essential amino acid. Glutamate, 
the anion of the Glutamic acid (Fig. 6), is the most abundant 
neurotransmitter present in the vertebrate nervous system (CNS)76. 
Since it was discovered77, this little molecule has been related to very 
important cellular functions and disorders78.  
 
Fig 6) Chemical representation of Glutamate (figure taken from 79). 
The first to sustain the synaptic function of Glutamate was Hayashi et al., 
who in 1954 injected Glutamate in the brain of mice and observed that 
provoked strong convulsions in the animal. Today, it is known that 
Glutamate mediates fast excitatory responses in both the CNS and 
Peripheral Nervous System (PNS) and regulates diverse neurological 
processes such as learning, memory, long term potentiation and synaptic 
plasticity76. Glutamate resides inside presynaptic vesicles and released in 
a Ca2+ dependent manner. This process comprises N and P/Q voltage-
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dependent Ca2+ channels80 localized in close proximity to the Glutamate 
filled vesicles80. Once Glutamate is released, it triggers the excitatory 
action postsynaptic potential (EPSP) by binding to the superfamily of 
specific Glutamate receptors (GluRs). 
Glutamate is part of the complex Glutamine-Glutamate-Gama Amino 
Butyric (GABA) Cycle (Fig 7)81. The synthesis of Glutamate starts in the 
astrocytes: glucose is taken up and converted in pyruvic acid by pyruvate 
carboxylase (PC). Pyruvate enters into the tricarboxylic cycle (TCA) and is 
converted to oxaloacetate (OAA) that condenses with Acetyl CoA to give 
rise to α-ketoglutarate. This last molecule can then be converted to 
Glutamate (and viceversa) by Glutamate Dehydrogenase (GDH)81. In the 
astrocytes, Glutamine Synthase (GS) converts Glutamate to Glutamine, 
that can now be transported to glutamatergic neurons by glutamine 
transporters and reconverted to Glutamate by Glutaminases82. Once 
Glutamate is released, the excess of this neurotransmitter is retaken by 
specific Glutamate transporters (reviewed later) and converted in 
glutamine by GS. Importantly, glutamine can also be transported in 
GABAergic cells to become transformed by GDH in Glutamate and 
posteriorly converted in GABA by the enzyme Glutamic Acid 
Decarboxylase 65 and 67 (GAD65/67)83,81.  
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Regarding to the Glutamate receptors, the neurotransmitter can bind 
either ionotropic (iGluR) or metabotropic GluRs (mGluR). iGluRs are 
predominantly post-synaptic ligand gated ion channels84. Structurally, 
these channels are formed by four subunits (iGluRI, iGluRII, iGluRIII and 
iGluRIV) and share the same organization: an extracellular amino 
terminal domain (ATD), a ligand binding domain (LBD), a transmembrane 
(TMD) and an intracellular carboxy terminal domain (CTD). A 
conformational change of the TMD occurs when Glutamate binds to the 
LBD allowing the influx of cations, more specifically sodium, potassium 
and calcium inside the cell84. Depending on their sensitivity to Glutamate 
co-factor agonists, the iGluRs are classified in three different categories: 
thea-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), 
Kaintate and N-methyl-D-aspartate (NMDA) iGluRs. 
AMPA (iGluR1 and iGluR4) and Kainate (iGluR5, iGluR7, KA1 and KA2) 
receptors are also referred to as non-NMDA84. They exert fast excitatory 
transmission by the influx of Na+ ions. NMDA (NR1, NR2A-D, NR3) receptors 
(NMDAR) give rise to a slow electrical transmission carried out by Ca2+ 
entry84. It is also common that NMDARs need glycine in combination with 
NMDA and Glutamate for their activation. In addition to the binding of 
the ligands, NMDARs require a partial membrane depolarization to 
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overcome the voltage sensitive block that is created by Mg2+ ions, 
normally present in the inner part of the channel84. 
 
Fig. 7) Glutamine-Glutamate-GABA cycle (taken from 81). Detailed explanation in the text. 
iGluRs are believed to have many more functions than just electrical 
transmission, such as pre-synaptic modulation and signal transduction, 
usually mediated by the interaction of their carboxy terminal with a wide 
variety of intracellular proteins84.  
In contrast, the mGluRs are G protein-linked metabotropic receptors 
constituted by an extracellular amino-terminal (ATD) where the ligand 
binds, a cysteine rich domain (CRD) crucial for protein dimerization as 
well as activation and a seven alpha helix transmembrane domain (TMD) 
followed by the intracellular carboxy-terminal (CTD)85. Apart for the 
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TMD, which is common to all the G protein coupled receptors (GPCR), 
the mGluRs share little homology with the other GPCR known. In 
addition, the mGluR family is formed by 12 members, some isoforms 
derived from differential splicing85, subdivided as follows in three 
categories based on the agonists molecule required for their activation: 
group I mGluRs (mGluR1 and m GluR5) are coupled with Gq proteins and 
activate Phopholipase C/Inositol 1,4,5-triphosphate/diacylglycerol 
(PLC/IP3/DAG) pathway. Groups II (mGluR2 and mGluR3) and III (mGluR4, 
mGluR6, mGluR7 and mGluR8) are coupled with Gi proteins and act on 
lowering cAMP levels86. Some mGluRs have long proline rich domains, 
named Homer1, that mediates their interactions with NMDARs and 
many other proteins87. Besides the CNS and PNS, the mGluRs were also 
found in various other tissues where they regulate subcellular 
homeostasis88. The mGluRs belonging to the group II and III are usually 
presynaptic and predominantly localized in the nervous system where 
they modulate the opening of ion channels. Group I mGluRs instead are 
predominantly localized in post-synaptic structures and found in the 
majority of tissues85. Figure 8 summarizes the GluRs classification. 
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Fig. 8) The GluRs classification. Detailed explanation in the text.  
Once Glutamate has bounded to the GluR and exerted its functions, it 
must be taken away from the synaptic cleft to allow the recovery of the 
system. Glutamate cleaning is mediated by a series of proteins, called 
excitatory amino acid transporters (EAAT), that are expressed in 
postsynaptic cells and supporting tissues such as the glia. So far, five 
different EAATs have been encountered in mammals: glial Glutamate 
and Aspartate transporter (GLAST or EAAT1) and glial Glutamate 
transporter (GLT-1 or EAAT2)89, both found in the glial tissue and three 
more in the nervous system, the excitatory amino acid transporter 3-5 
(EAAT3, EAAT4 and EAAT5)92. All of the transporters are Na+, H+ and 
probably Cl- co-transport and K+ counter-transport dependent89.  
Prolonged stimulation by Glutamate-GluR interaction is called 
excitotoxicity and is at the origin of many neurodegenerative diseases. 
Since a long time, Glutamate metabolism has been linked to ALS, AD, 
Parkinson, Huntington’s disease and many others90. In ALS, several 
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studies have addressed the role of AMPA receptors91. A recent study92, 
demonstrated a failure in ADAR2 mediated mRNA editing of the GluR2 
at the Glutamine/Arginine (Q/R) position in motoneurons of ALS 
patients. The lack of conversion from Adenosine to Inosine (A to I editing) 
makes the AMPA channel highly permeable to Ca2+, which in turn causes 
excitotoxicity and neuronal death92. The role of NMDAR and Kainate 
receptors, have been somehow neglected. Nonetheless, a study has 
shown NMDA/Ca2+-mediated excitotoxicity in the heavy neurofilament 
aggregated ALS mouse model93. Importantly treatment of excitotoxicity 
by GluRs antagonists has resulted in neuroprotection94, indeed the only 
FDA approved drug Riluzole, is a sodium channel antagonist and inhibitor 
of Glutamate release. AMPA antagonist GYKI 52466 was beneficial in 
SOD deficient cultured mouse neurons94. NMDARs mediated Ca2+ influx 
was blocked by NMDARs inhibitors MK-801 (dizolcipine), Memantine, 
Cerestat, Dextromethorphan and its metabolite Dextrorphan, all of 
which provided benefits after locally induced ischaemia94. 
Similarly, mGluRs overstimulation leads to neuronal disorders. When the 
group I of mGluR agonists are injected locally in the brain this results in 
epileptic manifestations95 and leads to cell death in combination with 
cerebral ischemia. On the other hand, mGluR group I antagonist 
61 
 
treatments are neuroprotective. In contrast, the treatment with mGluR 
group II agonists is neuroprotective after focally induced brain lesions96. 
Activation of these receptors at the level of astrocytes induce 
neurotrophic factors release which prevents NMDA excitotoxicity 
induced apoptosis97. 
Finally, EAATs impairment leads to excitotoxicity. Rothstein et al.98, have 
shown that loss of motoneurons was correlated with a reduction in the 
expression of GLT-1. In support of this idea, Glutamate transporter 
inhibitors caused degeneration of motoneurons98.  
 
3.2) GABA and related pathways 
GABA is the most important inhibitory neurotransmitter in the brain of 
mammals99. In humans, GABA (Fig. 9) is synthetized from Glutamate by 
GAD65 and GAD67 and shuttled in synaptic vesicles by Vesicular GABA 
transporter (vGAT). It can also remain cytosolic99 or leak from vesicles, 
ensuring a dynamic equilibrium of GABA cellular pools. When 
appropriate, GABA is released by Ca2+ dependent exocytosis100 in the 
synaptic cleft where it binds ionotropic (GABARA and GABARC) and 
metabotropic (GABARB) receptors causing the hyperpolarization and/or 
the activation of different cellular cascades. Depending on the type and 
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function of the GABAergic neurons releasing GABA, this 
neurotransmitter can act on a restricted number of neurons or in entire 
neuronal circuitries 99.  
Inhibition is crucial in maintaining neuronal network homeostasis and 
inhibitory cells are part of almost every neuronal circuitry. The primary 
role of GABA and GABAergic cells is to control that excitatory neurons 
within a neuronal network were not stimulated very often99. It should 
also be noted that GABAergic neurons are not merely limited to 
excitotoxicity prevention but have a wide range of important cellular 
functions related to the fine tuning of the brain electrical activity99 such 
as locomotor activity, reproduction, learning and circadian rhythms99. 
 
Fig. 9) GABA molecular structure (figure taken from 101). 
Ionotropic GABA receptors (GABARA and GABARC) are Cl- and HCO3- 
selective fast hyperpolarizing channels. GABARA is the best known, made 
from α, β, γ, δ and ε subunits organized in a heteropentamer102. 
Additional diversity within the subunits allow for more heterogeneity 
that is correlated with slightly different functions and tissue localization. 
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GABARC is found in the CNS and vertebrate retina, it has a 
homopentameric structure and can partner with GABARA102. Its role is far 
from clear.  
The metabotropic GABARB induce slow transmission currents and 
mediates several other neuronal effects by activating cellular effectors 
such as adenyl cyclases, voltage-dependent Ca2+ channels or inwardly 
rectifying potassium channels102. This receptor is found both pre and 
post-synaptically.  
The binding of GABA results in the release of the G associated protein 
subunits, which then diffuse and activate various intracellular signal 
cascades and, ultimately, lead to either the activation of post-synaptic K+ 
channels or the inhibition of pre-synaptic Ca2+ channels102. 
Disorders in the regulation of GABA metabolism have been linked to 
many neurodegenerative diseases, such as epilepsy, Parkinson’s disease, 
schizophrenia, anxiety disorders, autism, bi-polar disorder and PTSD 
(post-traumatic stress disorder)103. 
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3.3) Glutamic acid decarboxylase (GAD) 
GAD is the enzyme that catalyses the α-decarboxylation of L-Glutamate 
into GABA104. In humans, the enzyme is expressed in two isoforms, 
GAD67 (Fig. 10) and GAD65104. The isoforms are encoded by two genes 
(GAD1 and GAD2) located in different chromosomes (chromosome 2 and 
10 respectively). GAD67 and GAD65 are expressed in the brain, in 
pancreatic insulin producing B-cells, the oviduct and testis105. Additional 
transcripts of the enzyme are detected in the brain and come, most 
probably, from alternative splicing.  
GAD67 and GAD65, that weigh 67 and 65 kDa respectively, are highly 
divergent in the N-terminal part (just 23% of identity). This domain is 
involved in the intracellular localization, membrane association and 
homo/hetero-dimerization. On the contrary,  they are highly similar in 
the C-terminal part (73% of identity), a domain related to the catalytic 
activity of the enzyme103 and pyridoxal 5’-phosphate (PLP) binding site105. 
Both GAD67 and GAD65 need to homo/heterodimerize, auto-
phosphorylate and bind PLP to become active103. Structural studies have 
shown that the active site is formed by a flexible catalytic loop domain 
that goes from His 422 to Tyr 433103.  
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Fig. 10) GAD67 protein structure (figure taken from 106). GAD67 needs to 
homo/heterodimerize, auto-phosphorylate and bind PLP to become catalytically active. The 
active site and PLP binding region of the enzyme are found close to the C-terminal part of 
the protein. In contrast, the N-terminal domain is involved in localization, membrane 
association and dimerization of the protein.  
In the adult rat brains, GAD67 and GAD65 mRNAs are usually co-
expressed in the majority of neurons, but at different concentrations 
depending on the brain region. As Pinal et al.105 have observed, GAD65 is 
predominant in “the pyramidal layer of the olfactory tubercle, the 
superior colliculi, the lateral nuclei of the hypothalamus and several 
regions of the amygdala” whereas GAD67 is more abundant in “the 
granular layer of the olfactory bulb, the inferior colliculi, cerebellar 
cortex, neocortex and globus pallidus”. Also, GAD67 is more abundant 
during early development and after neuronal injury, possibly due to the 
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role of GABA as a trophic factor, whereas GAD65 is expressed later in 
development and is more important in synaptogenesis105.  
The enzymes can be found in soluble fractions or associated to 
membranes. The subcellular localization seems to depend on the post-
translational modification of their N-terminal part by phosphorylation 
and palmitoylation; but the exact mechanisms are still unknown107. 
Usually, GAD65 is membrane associated and localizes in the nerve 
terminals whilst GAD67 is found in the cell body and soluble fractions107. 
The different spatial and temporal expression patterns, would suggest a 
different function for the two isoforms. Accordingly, GAD67 accounts for 
up to 90% of GABA synthesis and is important for the maintenance of the 
vesicular and cytosolic GABA pools present in the mouse brains. In 
contrast, GAD65 is required for the maintenance of the vesicular synaptic 
pools after prolonged stimulation104. GAD67 is constitutively active 
whereas GAD65 predominantly appears as inactive, with the possibility 
of becoming rapidly activated upon the binding of PLP. Moreover, mice 
knockout for GAD67 (mGAD1) are lethal at birth in contrast to GAD65104.  
The gene GAD67 has at least two promoters that can be alternatively 
used at different developmental stages. In addition, GAD67 mRNA 
undergoes alternative splicing during the brain and spinal cord 
67 
 
development producing two shorter and inactive proteins called GAD25 
and GAD44105 after their respective molecular weights. These transcripts 
contain a start/stop codons inside an additional exon, that results in the 
translation of two different proteins. The truncated proteins are 
expressed in neuronal progenitor cells at day 13 of embryonic 
development and, consequently, GABA is not detected at that time105. By 
the day 17, some neurons start to transiently express the full GAD67 
protein resulting in GABA immunoreactivity105. Here, GABA is distributed 
in a diffuse manner throughout the neuronal cells. The early synthesis of 
GABA plays a trophic, rather than signalling role in neurotransmission. As 
the development of the brain progresses, GABA starts to localize in 
synaptic vesicles. These modifications coincide with the expression of 
GAD65 in late embryos and early postnatal life. At this point, the first 
mature synapses starts to form105.  
Importantly, as mentioned, GADs activation is achieved by the binding of 
the PLP co-factor to the GAD67 and GAD65 specific domains. These 
interactions depend on the levels of ATP and phosphate. These 
conditions are reached when the neuronal firing is intense, promoting 
the activation of GADs and the increased production of GABA during 
neuronal hyperpolarization105. It has also been found that GAD67 activity 
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is compromised during neurodegeneration. These findings were evident 
in patients suffering from Parkinson’s disease, who presented increased 
levels of GAD67 and GABA. In addition, the decrease in the sensory 
inputs after spinal cord transection in cats and rats resulted in increased 
levels of GAD67 mRNA105. In both circumstances, GAD67 increased 
activity was correlated with GABA’s trophic function and none of these 
changes were found for GAD65.  
Finally, many authors have found GADs autoantibodies in the serum of 
patients suffering from epilepsy, stiff person syndrome, cerebellar 
ataxia, limbic encephalitis, myoclonus and diabetes mellitus type 1, 
suggesting the implication of GADs in autoimmunity and related 
disorders108.   
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4) Drosophila melanogaster in the study of ALS, TDP-43 and 
Glutamate-GABA metabolism 
4.1) Drosophila melanogaster 
Drosophila melanogaster has been employed for more than 100 years in 
research. The first to make intensive use of this model system was 
Thomas Hunt Morgan (1866-1945). Inspired by Mendel’s theories, 
Morgan used the fruit fly to speculate about genes and their function, 
thus becoming one of the pioneers of genetics109. In 1933, he was 
granted a Nobel Prize in Physiology and Medicine for his discoveries 
about chromosomes and heredity. Soon after, Hermann Muller (1890-
1967) won a Nobel Prize in Physiology and Medicine for discovering that 
genetic mutations can be induced by x-ray irradiation. He, once again, 
took advantage of the fruit fly. There has been a well-rewarded history 
of scientific discoveries when Drosophila was employed. Many are the 
reasons why this model system is so advantageous in scientific research, 
some of them summarized in 109. Briefly, the rapid life cycle, the cheap 
cost of maintenance and the ease of use are some worth mentioning. 
However, the most important characteristic of this animal, that makes it 
an ideal model system in so many different fields, is certainly its genetics: 
compared to humans, the impressively high DNA sequence homology 
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that is reflected in so many well conserved cellular and physiological 
pathways between the two species. Yet even more important might be 
the ease of genetic manipulation.  
 
4.2) Drosophila’s life cycle  
 
Drosophila melanogaster is a dark bellied insect and dew eater with 
African origins belonging to Dipteria species. These sexually dimorphic 
animals allow easy recognition between male and female. The males are 
smaller, with black bristles on the forelegs called sex combs and a crown-
like reproductive organ situated on the end of the five-segmented 
abdomen, opposite to the black dorso. Females are bigger, have a seven-
segmented abdomen that ends with a less evident reproductive organ. 
In laboratory conditions, flies are usually kept on a 25% cornmeal 
medium in 10 cm long plastic tubes in chambers at 25ᵒC and 60% of 
humidity. In this environment, fecundated females can lay 0.5 mm long 
eggs (embryos) at a constant rate. The eggs will hatch and start growing 
into first instar larvae within 24 h after egg lay (AEL), second instar larvae 
within 48 h and third instar larvae within 72 h AEL (this last stage is 
divided in early and late and lasts 48 h). At approximately 120 h AEL, the 
larvae will enter into a process of metamorphosis that includes the 
71 
 
search for a dry place followed by transformation in pre-pupal and pupal 
stage. 120 h later, the adult fly will break and exit the pupal shall. From 
the time the embryos had been laid, it takes just 10 days for the adult fly 
to born (Fig 11). An adult fly lives typically 60 days. 
 
Fig. 11) Drosophila life cycle (figure taken from 110). Once laid, the embryo will start growing 
and differentiating in first, second and third instar larvae, will enter the pre-pupal and pupal 
stage and undergo metamorphosis, after which the adult fly will hatch the pupal shell. From 
the time the embryo has been laid, it takes only 10 days (at 25 °C) for an adult fly to be born.   
 
4.3) Drosophila’s genetics 
 
Drosophila has four pairs of chromosomes, three pairs of autosomes and 
one pair of sex chromosome. Genome sequencing revealed that the fly’s 
genome is 180 Mb long and contains approximately 13.600 genes. It has 
been showed, moreover, that there is high sequence similarity with 
many evolutionary complex species, such humans, especially regarding 
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genes involved in important molecular pathways such as gene 
expression, cell cycle and fundamental and well known metabolic 
processes.  
The ease of genetic manipulation makes Drosophila an ideal model 
system. Here I will summarize the most widely used genetic tools: 
1. Balancer chromosomes, first developed by Herman Muller, are 
multiply inverted stretches of nucleotides that harbour at least 
one phenotypic marker that expresses in a dominant manner. This 
genetic tool prevents the process of meiotic recombination 
between the homologous chromosomes, assuring the integrity of 
the genetic construct inserted in the genome (note that 
Drosophila males do not undergo meiotic recombination) and 
helps in following the insert through fly generations. 
There are several balancers designed for chromosomes X, II and III 
(recombination does not occur on the IV chromosome). The most 
widely used are the balancer CyO of the II chromosome, that 
expresses curly wings, TM3SB and TM6B of the III chromosome, 
that expresses short or thick bristles and tubby larvae/pupae 
respectively.  
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2. P-elements are transposons specific for Drosophila. These elements 
can be manipulated to jump and create deletions inside genes of 
interest in the genome of the fruit fly. They can be autonomous or 
non-autonomous, depending on the presence of the transposase 
gene. When creating gene deletions, a combination of an 
autonomous but immobile transposon111 and several non-
autonomous mobile elements is used. A second use of this tool is to 
create transgenic flies111. In this case, a plasmid containing the gene 
of interest and the p-element sequence is created and then injected 
in pre-blastoderm embryos in addition to the plasmid containing the 
gene for the transposase. The p-element will jump randomly across 
the fly genome allowing the insertion of the desired gene. Recently, a 
site-specific transformation system has been created that allows the 
insertion of the p-element site-specifically112. The successful 
integration of the p-element is validated by PCR. 
 
3. The GAL4-UAS expression system, developed by Brand and Perrimon 
in 1993113, allows tissue specific gene expression. The system takes 
advantage of the S. cereviseae GAL4 transcription factor, a 881 amino 
acids long protein that does not have a particularly toxic effect on flies 
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even at high expression levels. The GAL4 binds to 17 bp long cys-
regulatory enhancer elements called Upstream Activating Sequences 
(UAS) promoting the assembly of the transcriptional machinery and, 
consequently, gene expression. For the system to work, the sequence 
for the GAL4 must be inserted downstream a tissue specific promoter, 
creating a so-called “driver” (e.g. Actin-GAL4, Elav-GAL4, Repo-
GAL4,…), and the UAS sequence must be inserted upstream of the 
gene of interest. Usually, two different Drosophila stocks are created, 
one harbouring the GAL4 and the other harbouring the UAS 
sequence. When these stocks are crossed together, the progeny will 
express a tissue specific GAL4, that will bind and overexpress the gene 
of interest only in that tissue. This system can be used also to silence 
genes of interest, when a target gene RNAi is inserted downstream of 
the UAS sites.   
 
4.4) Neural development in Drosophila 
 
Drosophila’s nervous system has been intensively studied and incredibly 
helpful in understanding the processes of neurodevelopment and 
neurodegeneration. The nervous system in Drosophila is of ganglionic 
type. The CNS is made of the central brain and the ventral nerve chord, 
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while the PNS consists of nerve fibers that extend from the CNS. During 
development, the neurons and glial cell bodies form the outer layer that 
surrounds the inner neuropile, a region where axons and branches 
extend into and create bundles114. These bundles can extend for long 
distances and create neural pathways called commissures115.  
Drosophila neurogenesis starts early in embryonic development, when 
the ectoderm is subdivided into the epidermal ectoderm and the 
neuroectoderm116. A subset of neuroectodermal cells will give rise to 
neuroblasts (NB), stem-like cells from which neurons and glia will later 
form116. Drosophila CNS begins as a cluster of ∼ 100 NBs as early as stage 
9 of embryonic development117. NBs will start dividing in a stem-like 
fashion, each giving rise to a ganglion mother cell (GMC) and a NB. The 
GMC will divide into two primary neurons which will start extending their 
first axons towards the neuropile117. During larval development, the NBs 
will divide again, giving rise to secondary neurons. All neurons that derive 
from a specific NB belong to the same “lineage” (Fig. 12). Some NB 
lineages will give rise to Raw Prawn (RP) neurons – Drosophila 
motoneurons119. There are 5 well characterized RPs (RP1-5). Since it is 
inherent to the experimental work in this thesis, RP3 will be discussed in 
more detail: the cell body of RP3 starts migrating towards the ventral 
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midline of the ventral nerve chord at stage 12 and extending its first 
growth cones at stage 13119. 
 
Fig. 12) Drosophila larval CNS. The CNS of a developing larvae is made of the central brain 
(CB) that includes two optic lobes (OL), and the ventral nerve chord (VNC). The brain begins 
as a cluster of ∼ 100 NBs. NBs will start dividing in a stem-like fashion giving rise to GMC that 
will later differentiate into neurons and glial cells. Soon after, the neurons will extend their 
axons towards the neuropile and into commissures (figure taken from 118 and 117).  
RP3 will extend a prominent contralateral axon which will enter the 
Intersegmental Nerve (ISN), exit the CNS and join the Segmental Nerve 
(SN) in the PNS, ultimately ending to make close contact with muscles at 
stage 14119. RP3 will continue extending its processes, until it reaches its 
target muscles, ventral muscles 6 and 7, at stage 16 (Fig. 13). 
Coincidently, this is also the time when the first muscular movements 
become apparent. Detailed information about development of 
Drosophila growth cones and muscle innervation are found in 119. 
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Fig. 13) The RP lineages and the innervation of muscles. RP3 migrates towards the VNC and 
starts extending a prominent contralateral axon that will exit the CNS following the ISN and 
enter the SN in the PNS, ultimately innervating muscle 6 and 7 (figure taken from 119). 
 
4.5) Drosophila’s neuromuscular junctions 
 
The Drosophila neuromuscular junction (NMJ) is a powerful platform for 
the study of synaptic development and neurotransmission120. The NMJ is 
the place where motoneurons make contact with their target muscles. 
Drosophila offers the possibility to study this interaction on a single cell 
resolution. Almost all the studies are performed on larval abdominal 
segments which present a simple and accessible organization. Each 
muscle fiber is multinuclear, formed by the fusion of several myoblast 
and organized in A1 to A7 segments, with about 30 muscle fibers per 
segment (A1 differs in this organization)121 (Fig. 14).  
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Fig. 14) Drosophila larvae neuro-muscular structure. On the left: Schematic representation 
of third instar larva muscle structure and its innervation pattern. On the right: schematic 
magnification of second abdominal segment in third instar larva, with special focus on the 
motoneuron laying on the muscle 6 and 7.  
Each motoneuron interacts with two or more muscle fibers121. 
Neuromuscular development starts as soon as stage 14 of embryonic 
development, when the specialized processes called myopodia extend 
from the muscle fibers to make their first contact with motoneuron’s 
growth cones122. When this interaction has occurred, GluRs start to 
cluster in the post-synaptic areas of the muscles, followed by the 
maturation of pre-synaptic boutons, pre-synaptic vesicles and the 
formation of the active zones at stage 16 of development123. Initially, 
these structures are very primitive and comprise few boutons with no 
branches. During development, consequently to the spreading of 
branches and boutons, the motoneurons start to expand on the surfaces 
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of muscles. At late 3rd instar larval stage, these structures increase in 
their volume and facilitate the recognition of the neuromuscular 
networks. 
 
4.6) Neuron-glia interaction in Drosophila 
 
The vast majority of cells in the human brain (90%) are glial cells124. The 
glia has essential functions in regulating the brain development and 
homeostasis. During development the glia regulates neural stem cell 
proliferation, provides trophic factors for growing neurons, guides axon 
pathfinding, ensheaths axons, promotes synaptic formation and 
maturation and eliminates neuronal waste124. In the mature nervous 
system, the glia maintains ionic equilibrium, regulates neurotransmitter 
re-uptake from the synaptic cleft and modulates synaptic activity by 
associating with synaptic terminals124. In addition, glial cells are the 
major immune cells in the CNS124. Despite all these important roles, we 
know very little about the glia, and this is partly because it is very 
challenging to study this tissue on a single cell resolution.  
Drosophila’s glia shares the majority of these functions with its human 
counterpart. Glial cells in Drosophila are classified as follows: in the CNS, 
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I) surface glia, that covers the entire surface of the brain, and is further 
subdivided in perineurial (outer) and subperineurial (inner) layer glia; II) 
cortex glia, that ensheaths neuronal and NBs cell bodies; III) neuropile 
glia, that is located between the cortex and the neuropile, and is further 
subdivided in ensheathing glia (remains at the neuropile surface) and 
astrocyte-like or reticular glia (surrounds nerve fibers inside the 
neuropile)125. In the PNS, we recognize I) perineurial and II) 
subperineurial glia, that form the septate junctions seal; III) wrapping 
glia, that surrounds the individual axons125.  
Drosophila’s PNS glial cells derive from NBs lineages, nearly all brain NBs. 
These cells migrate out of the CNS along the extending axonal tracts of 
motoneurons, following the ISN and SN. As the development goes on, 
glial cells grow in size and wrap around axons and axon fascicles126.  
Drosophila’s genetic toolbox has allowed the study of the lack-of-glia 
effects on the organization of the CNS and PNS. The lack of gene gcm, 
the master regulator of glial development, was associated with severe 
defects in axon guidance, nerve ensheathment and fasciculation126.  
Gmc-/- embryos have aberrant CNS longitudinal nerve tracts including 
complete disorganization of the ISN and SN. The absence of glial 
wrapping onto individual axons results in their morphological deficits, 
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degeneration and problems in signal conducatance126. These are just 
some of the deficits caused by the lack-of-glia, suggesting the importance 
of this tissue in promoting neuronal homeostasis.  
 
 
4.7) Neurotransmission in Drosophila 
Neurotransmission is made possible by a complex network of 
functionally specialized synaptic proteins. The evolutionally conserved 
family of Synapsins govern the release of presynaptic vesicles filled with 
neurotransmitters127. These proteins called SNAREs (Soluble N-
Ethylmaleimide sensitive fusion attachment protein receptors) can be 
found on both pre-synaptic and vesicular membranes. Vesicle release is 
dependent on the phosphorylation status of SNAREs, which is governed 
by intracellular signal cascades, usually an arriving action potential that 
leads to a rise of presynaptic Ca2+ and activation of Ca2+/Calmodulin 
dependent kinases. The interaction between vesicular SNAREs (vSNARES 
– synaptobrevin, synaptogamin), and pre-synaptic membrane SNAREs 
(tSNAREs – syntaxin, SNAP25) will lead to vesicle-membrane fusion, 
neurotransmitter exocytosis and vesicle recycling128. An important pre-
synaptic protein in Drosophila is Bruchpilot, with homology to vertebrate 
CAST (Cytoskeletal matrix associated with the active zone structural 
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protein), involved in the maturation of T-Bars, structures that promotes 
vesicle scaffolding129.  
Neurotransmitter release occurs in the active zones of the synaptic cleft, 
with consequent binding to the post-synaptic receptors and signal 
propagation. First thing to mention is that the fruit fly uses Glutamate 
(therefore glutamatergic synapses) in both the brain and the NMJs, 
which contrasts with mammals that use Acetylcholine (Ach) and 
Cholinergic Receptor (AchR) to communicate at the level of NMJ and 
Glutamate-GluR only in the brain (although some studies suggest the 
existence of glutamatergic synapses at the NMJ in humans as well130). 
Most of the invertebrates use glutamatergic synapses at the NMJ, so 
mammals are an oddity in evolution.  
Like in the mammals, Drosophila’s GluRs can either be ionotropic or 
metabotropic. iGluRs in Drosophila are subdivided in 1) NMDA 
dependent, 2) NMDA non-dependent and 3) Glutamate-gated chloride 
channels. The first group of NMDA-like proteins (dNR1/NMDAR-I and 
dNR2/NMDAR-II) are similar to human’s NMDARs131, activated by 
Glutamate and NMDA, modulated by Glycine and with a Mg2+ voltage 
sensitive block. They are mainly spread in the fly’s brain where they 
modulate learning processes.  
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The best studied iGluRs in Drosophila, however, are certainly the NMDA 
non-dependent. These receptors are found in the embryonic and larval 
body muscles. Depending on the type of electrical transmission and the 
subunits that form the protein complex, non-NMDA receptors are 
further subdivided in type A (excitatory, GluRIIA + GluRIIC/GluRIII + 
GluRIID + GluRIIE + the accessory subunit Neto) and type B (excitatory, 
GluRIIB + GluRIIC/GluRIII + GluRIID + GluRIIE + the accessory subunit 
Neto)132. Despite the structural similarity to human receptors, 
Drosophila’s non-NMDA GluRs are activated by Glutamate and 
Quisqualate but not Glycine, GABA, Acetylcholine, NMDA, or Kainate132, 
therefore they are not to be considered AMPA or Kainate receptors.  
The Glutamate-gated Chloride channels type H, are inhibitory channels 
but their functions were not clearly elucidated yet. 
Only two mGluR-like proteins have been encountered in the fly: 
dmGluRA and dmXR. The former is similar to human mGluR group II, 
found predominantly in the brain where it regulates learning133 or at pre-
synaptic terminals, where its function is unknown. DmXR has not yet 
been well characterized133. Detailed information on Drosophila GluRs can 
be found in 133.  
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The clustering and recycling of GluRs is promoted by Disc-Large, a 
scaffolding protein of the post-synaptic membranes that belongs to the 
evolutionally conserved family of Membrane Associated Guanylate 
Kinases (MAGUK), widely expressed in neurons and glia of vertebrates. 
Disc Large 1 is the exclusive ortholog in Drosophila134.  
 
4.8) Drosophila GAD1  
The two GAD ortholog genes in Drosophila, GAD1 and GAD2135, generate 
two different proteins. Drosophila GAD1 has a mass of 57 kDa and a 
length of 510 amino acids. This protein shares 53% of total identity with 
its mammalian counterpart that increases to reach the 70% of identity in 
the C-terminal, the PLP binding domain. Biochemical analysis revealed 
that dGAD1 catalyses the production of GABA from Glutamate with an 
efficiency and kinetics similar to the mammalian GAD136. dGAD1 is 
widespread in the nervous system from the early stages of 
embryogenesis till late adulthood. dGAD2, instead,  shares 42% of 
identity and encodes a 58 kDa protein137. dGAD2 heterozygous flies 
showed, however, normal levels of GABA. Moreover, it seems that 
dGAD2 is expressed just in the glia indicating that dGAD1 is the more 
important for the GABA metabolism in neurons137. 
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Insects homozygous mutants for dGAD1 enzymatic activity display 
severe locomotive and behavioural defects and die at embryonic or first 
instar larvae stages136. The pan-neuronal overexpression of dGAD1 
rescues completely these phenotypes indicating that the protein is 
essential in the neurons for survival136. dGAD1 is present in the cell 
bodies, axons and synaptic boutons of third instar larvae, in both the CNS 
and the PNS (Fig. 15)136.  
In the NMJ, dGAD1 is required to regulate the levels of Glutamate and 
ensure the proper GluRs receptor field organization. Featherstone et 
al.,136 observed that, despite the high concentration of dGAD1 in the 
motoneurons synaptic terminals, there was no GABA immunoreactivity 
and the injection of GABA was not producing any transmission event 
indicating that GABA may not have synaptic functions in flies NMJs. In 
contrast, Glutamate was required. Thus, the neurotransmission in 
dGAD1 mutants was highly impaired. The phenotype was a consequence 
of a 4-5 fold reduction in the number of post-synaptic GluRs compared 
to wild type136. These studies demonstrated that pre-synaptic dGAD1 is 
required to orchestrate the organization of GluRs in the post-synaptic 
membrane of the flies NMJs. These findings go along with the theory that 
indicates that the communication between pre-synaptic and post-
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synaptic networks is dictated by the release of pre-synaptic signalling 
molecules136. 
 
Fig. 15) GAD1 localization and the effects of GAD1 genetic manipulation on the GluRs field at 
Drosophila’s NMJs (figures taken from 136, 138). On the left: GAD1 naturally localizes in the 
motoneurons pre-synaptic terminal in wild type larvae. On the right: GAD1 mutant larvae 
have reduced GluRs field in the NMJs. 
In the NMJs of vertebrates, Agrin and Neuroregulins are secreted by the 
pre-synaptic neurons to initiate the expression and clustering of AChR on 
the muscle surface. In Drosophila, it seems that the concentration of 
Glutamate is critical to accomplish the analogous processes.  
Two years later, Featherstone et al.138, observed that “the size of the 
postsynaptic Glutamate response was inversely correlated with the 
presynaptic levels of Glutamate”. In this study, the group concluded that 
the downregulation of GluRs in dGAD1 mutants was mediated by an 
excess of Glutamate in the synaptic cleft, released by a non-vesicular 
mechanism. They proposed that Glutamate (thus the dGAD1 by-product) 
87 
 
would have two distinct functions in the NMJs of flies: the first one is 
related to its well-known role in the propagation of action potentials 
mediated by the vesicular release of Glutamate. The second one, relates 
to the slow and constant non-vesicular release of the neurotransmitter 
and is intended for the expression and clustering of GluRs at the post-
synaptic membranes138.  
 
4.9) Drosophila in the study of ALS and TDP-43 
In recent years great efforts has been invested in the study of ALS using 
the fruit fly. Many models have been created with the aim of simulating 
the disease in this animal. Manipulation of the main genes thought to be 
involved in the appearance of ALS, such as C9ORF72, SOD1 and TDP-43 
have been performed in the fly139,140,141. 
In 2009, Feiguin et al.142, generated a deletion of the gene TBPH, the 
homolog of TDP-43 in the fruit fly. Protein alignment has shown 59% of 
identity in the RRM region between these two orthologs suggesting high 
structural and functional conservation56. TBPH deletion completely 
abolished the endogenous expression of the protein (TBPH null flies) (Fig 
16). Flies lacking TBPH had reduced life span and strong locomotor 
impairments due to structural defects at the level of NMJs (Fig 16)142. In 
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addition, it was discovered that TBPH silencing in neurons provoked 
clustering deficits of pre-synaptic proteins Syntaxin, Synapsin and 
Cystein String Protein (csp) and post-synaptic proteins Disc Large and the 
GluRIIA (Fig. 17) at the level of larval NMJs. On the contrary, the pre-
synaptic protein Bruchpilot was not affected (Fig. 17). Similarly, silencing 
of TBPH in the glia provoked life span reduction and locomotion 
problems, accompanied with GluRIIA clustering alterations and also the 
retraction of glial wrapping around motoneurons. These data indicated 
that TBPH promoted the assembly of proteins at the synaptic terminals 
in both neurons and muscles, acting from different tissues, and thus had 
a pivotal role in the structural and functional complexity of the 
Drosophila’s NMJs. These proteins were also downregulated at protein 
level, indicating that it was not a problem of transport or localization but 
rather of gene expression. 
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Fig. 16) Loss of TBPH expression in Drosophila is associated with reduced life expectancy, 
locomotion impairment and neuro-muscular junctions deficits (figure taken from 142). In 
2009, Feiguin has abolished the expression of endogenous TBPH by creating two different 
deletions models (TBPHΔ23/ Δ23, TBPHΔ142/ Δ142) inside the promoter region of Drosophila TBPH 
gene. 
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Fig. 17) Reduced expression of TBPH in Drosophila neurons (TE-TBi) is associated with 
reduced clusterization of Syx, Syn, Csp on the pre-synaptic membrane, Dlg and GluRIIA on 
the post-synaptic membrane, at the Drosophila larval NMJs. Hrp is a glycoprotein of neuronal 
membranes (figure taken from 143). 
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AIM OF THESIS 
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In this PhD thesis, my aims were to investigate the proteins that 
intermediate the role of TDP-43 in the organization of the synapses using 
a TDP-ALS fly model. More specifically, the questions addressed were the 
following: 
- To investigate which proteins are directly or indirectly regulated 
by TDP-43 by performing TBPH null wide screen proteomic 
analysis 
 
- To understand the role of these proteins in neuronal and non-
neuronal tissues by genetically manipulating their expression 
 
- To study how these proteins influence synaptic communication by 
measuring their activity  
 
- To investigate if these molecular pathways are conserved in 
humans and ALS patients 
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RESULTS 
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5) Proteomic alterations in TBPH null flies 
5.1) The enzyme GAD1 is downregulated in TBPH null brains 
In the first part of this study, we performed a genome wide high 
throughput proteomic analysis aiming to identify all the molecules that 
were translationally misregulated in TBPH mutant flies compared to wild 
type controls. To do so, we carried out a two-dimensional gel 
electrophoresis between 1-day old Drosophila adult heads from wild 
type (w1118) as well as TBPH null alleles (TBPHΔ23/Δ23 and TBPHΔ142/Δ142) and 
analysed statistical differences in spot intensities after normalization. 
We fixed a 1.5 threshold and obtained a total number of 35 modified 
spots out of 1383 examined (Fig. 18). We then selected the spots that 
were similarly modified in both mutants (TBPHΔ23/Δ23 and TBPHΔ142/Δ142) 
for a total number of 7 spots, 5 downregulated and 2 upregulated. The 
proteins corresponding to these spots were extracted and sent to 
MALDI-TOF mass spectrometry analysis for identification. Among the 
downregulated proteins, GAD1 (cg14994, FBgn0004516) was the most 
prominent (Fig. 19). GAD1 is an evolutionary conserved enzyme that 
converts Glutamate to GABA. Since these fundamentally important 
neurotransmitters promote synaptic communication, GAD1 
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downregulation could explain TBPH null neurodegeneration, especially 
related to the loss of synaptic stability that these mutants exhibit.  
 
Fig. 18) Genome wide proteomic analysis of TBPH null adult flies heads. 2D gel 
electrophoretic analysis of TBPH null adult heads showed several spots whose intensities 
were altered (highlighted in blue) in respect to wild type. GAD1 protein (corresponding to 
spot 701) was one of the spots that resulted downregulated (shown in red). Genotypes: 
w1118, TBPHΔ23/Δ23 and TBPHΔ142/Δ142. n=100 per genotype (technical procedures for 2D gel 
analysis are explained in the text and in more detail in the Material and Methods section). 
Courtesy of Dr. Raffaella Klima and Prof. Rodolfo Garcia. 
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Fig. 19) Magnification and quantification of the downregulated spot 701 in 2D gel 
electrophoresis of TBPH null adult flies heads. The enzyme GAD1 is one of the proteins 
downregulated in both TBPHΔ23/Δ23 and TBPHΔ142/ Δ142 in comparison to w1118. Beneath are the 
intensity quantification for GAD1 protein after normalization, total n was 100 per genotype 
(the quantification of spots intensities is explained in the text and in more detail in the 
Material and Methods section). Courtesy of Dr. Raffaella Klima and Prof. Rodolfo Garcia. 
Next, we decided to confirm this result by western blot. Unfortunately, 
the only available antibody that recognizes Drosophila GAD136,  was not 
provided to us. For this reason, we used a fly (GAD1MIMIC/Tm3sb) that 
carried an endogenously tagged GAD1 gene.  In brief, a MIMIC cassette 
comprehending a triple flag tag was inserted in the middle of the coding 
region of GAD1 gene (w;Mi{MIC}GAD1MI09277/+). The protein encoded by 
this gene was supposed to weight approximately 95 kDa, that is the 
combined mass of GAD1 protein (57.8 kDa) and the MIMIC cassette 
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(EGFP-FlAsH-StrepII-TEV-3xFlag-tag insertion) (35kDa). We have then 
constructed a fly carrying this construct in a TBPHΔ23 background 
(TBPHΔ23/yGFP; GAD1MIMIC/Tm6b) and crossed to TBPHΔ23/yGFP to obtain 
a fly expressing the tagged GAD1 in a TBPH null background (TBPH Δ23/Δ23; 
GAD1MIMIC/+). This fly was compared to TBPH +/+; GAD1MIMIC/+. The brains 
of third instar larvae were lysed and labelled with anti-flag M5 in western 
blot. The data clearly indicated that of GAD1MIMIC was downregulated in 
TBPH mutant larvae in comparison to the controls, confirming the 
proteomic findings (Fig. 20).  
 
Fig. 20) GAD1MIMIC protein levels in TBPH null larvae. Western blot showed that GAD1MIMIC is 
downregulated in TBPH null third instar larval brains in respect to controls. The antibody 
against GAD1 was not available to us, therefore we visualized GAD1MIMIC (MIMIC being a tag 
insertion in the middle of the GAD1 allele). The samples were run on polyacrylamide gels, 
transferred and labelled with a-Flag M5 and a-Tubulin primary antibodies. Data were 
normalized, n=20 per genotype. Beneath is the normalized quantification of bands’ intensity 
(a-FlagM5/a-Tubulin) that was done in ImageJ (more in detail in the Material and Methods 
section). Courtesy of Dr. Giulia Romano. 
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To test GAD1 mRNA levels, we performed a real time PCR (RT-PCR) 
against GAD1 mRNA in TBPH null third instar larvae (Fig. 21). The data 
indicated that GAD1 mRNA is downregulated in TBPHΔ23/Δ23 and 
TBPHΔ142/Δ142 compared to w1118. In summary, these results 
demonstrated that GAD1 was downregulated in TBPH mutants at both 
the transcriptional and translational level. These results were extremely 
interesting given the function of TBPH as a RNA binding protein and 
regulator of RNA metabolism. Naturally, one would assume that TBPH 
could directly bind and positively regulate GAD1 pre-mRNA (or mRNA) 
and that GAD1 mRNA downregulation in TBPH null flies was due to the 
obstruction of this TDP-dependent regulatory step. Thus, we performed 
immunoprecipitation studies to test TBPH-GAD1 mRNA interaction. 
However, despite intensive efforts, we were not able to observe any 
direct binding between the two (data not shown), indicating that GAD1 
mRNA was processed by different molecules.  
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Fig. 21) mRNA levels of GAD1 in TBPH null larvae. RT-PCR demonstrated that GAD1 mRNA is 
downregulated in TBPH null third instar larval brains (both TBPHΔ23/Δ23 and TBPHΔ142/Δ142) in 
comparison to wild type (w1118). mRNA levels were normalized on Rpl11, a housekeeping 
gene. Quantification was done in GraphPad Prism 7.0, ***p < 0.001 calculated by one-way 
ANOVA. Error bars SEM. n=20. Courtesy of Dr. Giulia Romano. 
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6) The role of GAD1 in neurons 
6.1) The reintroduction of GAD1 in neurons rescues the TBPH 
null motility defects 
In our previous experiments we assessed that GAD1 was downregulated 
in TBPH mutants. To establish whether this enzyme played a role in TBPH 
null flies motility phenotypes, we reintroduced GAD1 in neurons of TBPH 
mutant flies taking advantage of the GAL4-UAS expression system. To do 
so, we used a fly that was carrying GAD1 gene placed under UAS control 
(uasGAD1), allowing the transgene to be expressed in a controlled and 
tissue specific manner. We therefore discarded the fly carrying 
GAD1MIMIC, a mutated form of the endogenous gene, used earlier to 
quantify the expression of the endogenous protein. We specifically 
utilized Elav-GAL4, a pan-neuronal driver and D42-GAL4 a driver specific 
for motoneurons and measured the locomotion performance of third 
instar larvae and adult flies. Our data showed that GAD1 reintroduction 
in neurons and motoneurons significantly rescued the locomotion 
impairments of TBPH null larvae (Fig. 22). This rescue was observed only 
at larval stage but not in the adult flies (data not shown), indicating that 
the adult developmental stage involved more complex degeneration 
pathways that were not limited to GAD1 downregulation. In parallel, the 
101 
 
reintroduction of exogenous TBPH yielded a stronger recovery of these 
genetics backgrounds, in both larvae and adult flies (not shown), 
suggesting that GAD1 could only partially replace TBPH. In summary, 
these results indicated that GAD1 downregulation played a role in TBPH 
null motility defects and its reintroduction rescued, although only 
partially, the locomotion phenotypes.  
 
Fig. 22) GAD1 overexpression in pan-neuronal tissues in TBPH null larvae. GAD1 
reintroduction (Δtb-GAD1) in neurons by Elav-GAL4 and D42-GAL4 drivers have significantly 
recovered the motility defects of TBPH null third instar larvae compared to the negative 
control (Δtb-GFP). Recovery was calculated measuring the number of larval waves the 
animals were performing in 2 min. Genotypes: w1118, Δtb-GFP (on the left: Elav-GAL4, 
TBPHΔ23/Δ23; uasGFP/+ and on the right: TBPHΔ23/Δ23; uasGFP/D42-GAL4,) Δtb-GAD1 (on the 
left: Elav-GAL4, TBPHΔ23/Δ23; uasGAD1/+ and on the right: TBPHΔ23/Δ23; uasGAD1/D42-GAL4) 
and Δtb-TB (on the left: Elav-GAL4, TBPHΔ23/Δ23; uasTBPH/+ and on the right: TBPHΔ23/Δ23; 
uasTBPH/D42-GAL4), Quantification was done in GraphPad Prism 7.0, **p < 0.01, ***p < 
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0.001 calculated by one-way ANOVA. Error bars SEM. Total number of tested animals per 
genotype was 25.  
 
6.2) The reintroduction of GAD1 does not rescue motoneurons 
terminal growth  
We have established that GAD1 rescued TBPH null motility defects and 
suspected that the role played by GAD1 was related to the regulation of 
synaptic homeostasis. Accordingly, we have previously discovered that 
the neuronal growth depends strictly on the stability of the synaptic 
communications and that both, the neuronal branching and the shape of 
the synaptic boutons were highly compromised in TBPH null flies. 
Therefore, we first decided to investigate whether GAD1 was able to 
recover the morphological integrity of motoneurons. For these 
experiments, we dissected and labelled third instar larvae against HRP, 
an antigenic glycoprotein present in neuronal membranes144. Next, we 
measured the number of branches and the number of spherically shaped 
synaptic boutons that motoneurons can extend on the surface of 
muscles 6 and 7 in the second abdominal segment. We noticed that none 
of these parameters were ameliorating upon GAD1 reintroduction (Fig. 
23). Although disappointing, these results were not surprising as 
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previous studies have shown that TBPH regulates the organization of 
microtubules by directly binding and regulating Futsch mRNA61, the 
Drosophila microtubule associated protein. Thus, it seemed that GAD1 
reintroduction was not able to replace TBPH functions that are related 
to the morphological structure of the pre-synaptic terminal suggesting 
that GAD1 rescue of TBPH null locomotion impairment was independent 
of the pre-synaptic morphological growth.  
 
Fig. 23) Motoneuron branching and synaptic boutons shape integrity in TBPH null larvae 
upon GAD1 overexpression in neurons (Elav-Δtb-GAD1). This figure indicates that GAD1 
reintroduction did not ameliorate neuronal branching or boutons shape integrity of TBPH 
null larvae in comparison to the negative control (Elav-Δtb-GFP). Above: confocal microscopy 
acquisition of the motoneuron laying on the muscles 6/7 of the second abdominal segment 
of third instar larvae. The nerve cell was stained with anti-HRP, a glycoprotein of outer 
neuronal membranes. Below: quantification of 1b boutons and synaptic branches 
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ramification of the motoneurons. Genotypes: w1118, Elav-Δtb-GFP (Elav-GAL4, TBPHΔ23/Δ23; 
uasGFP/+) and Elav-Δtb-GAD1 (Elav-GAL4, TBPHΔ23/Δ23; uasGAD1/+). Quantification was done 
in GraphPad Prism 7.0, ***p < 0.001 calculated by one-way ANOVA. Error bars SEM. Scale 
bar: 10 µm. 15 larvae examined per genotype. 
 
6.3) The reintroduction of GAD1 in neurons rescues the pre-
synaptic protein Syntaxin and the post-synaptic proteins Disc 
Large and GluRIIA 
GAD1 reintroduction was not recovering the morphological integrity of 
motoneurons. However, these evidences were not ruling out the 
possibility that GAD1 could ameliorate the synaptic communication 
between the motoneurons and the muscle. We knew from previous 
studies143 that several pre-synaptic and post-synaptic proteins were 
downregulated in TBPH mutants. The pre-synaptic protein Syntaxin and 
the post-synaptic Disc Large and GluRIIA proteins are few examples. To 
investigate if their distribution was rescued by GAD1 reintroduction, we 
performed a series of dissections and labelled third instar larvae NMJs 
against Syntaxin, Disc Large and GluRIIA. As an internal control we used 
the pre-synaptic protein Bruchpilot, shown to be unaffected in TBPH null 
flies143. 
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Our data indicated that GAD1 reintroduction significantly rescued the 
distribution of Syntaxin (Fig. 25) on the pre-synaptic membranes and the 
distribution of Disc Large (Fig. 26) and GluRIIA (Fig. 27) on the post-
synaptic terminals. Bruchpilot, instead, remained unaltered (Fig. 24) 
confirming the reliability of this internal control. As these proteins tightly 
regulate synaptic communication, these results could indicate that GAD1 
rescue of TBPH null motility defects was driven by an enhancement in 
synaptic communication between neurons and muscles. In addition to 
the evident rescue of post-synaptic proteins Disc Large and GluRIIA, it 
was surprising to observe that Syntaxin, a pre-synaptic protein that is 
naturally directly bounded and regulated by TBPH61, was also partially 
rescued by GAD1 reintroduction in neurons.  
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Fig. 24) Distribution of pre-synaptic protein Bruchpilot in the NMJ of TBPH null larvae upon 
GAD1 overexpression in neurons (Elav-Δtb-GAD1). Bruchpilot distribution was not affected 
in TBPH null flies. We used this protein as an internal control. Our quantification showed that 
Bruchpilot distribution remained unchanged in the tested samples. On the left: confocal 
microscopy acquisition of the motoneuron laying on the muscles 6/7 of the second 
abdominal segment of third instar larvae. The nerve cell was stained with anti-HRP (green, 
merged to Brp) and anti-Brp (red). On the right: quantification of Brp/Hrp intensity. 
Genotypes: w1118, Elav-Δtb-GFP (Elav-GAL4, TBPHΔ23/Δ23; uasGFP/+) and Elav-Δtb-GAD1 (Elav-
GAL4, TBPHΔ23/Δ23; uasGAD1/+). Quantification was done in GraphPad Prism 7.0, ns = non-
significative (not shown), calculated by one-way ANOVA. Error bars SEM.  Scale bar: 5 µm. 
n>200 boutons per genotype. 
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Fig. 25) Distribution of pre-synaptic protein Syntaxin in the NMJ of TBPH null larvae upon 
GAD1 overexpression in neurons. Syntaxin was previously described to be downregulated in 
TBPH null flies. GAD1 reintroduction in neurons (Elav-Δtb-GAD1) rescued significantly the 
distribution of Syntaxin in comparison to the negative control (Elav-Δtb-GFP). On the left: 
confocal microscopy acquisition of the motoneuron laying on the muscles 6/7 of the second 
abdominal segment of third instar larvae. The nerve cell was stained with anti-HRP (green, 
merged to Syx) and anti-Syx (red). On the right: quantification of Syx/Hrp intensity. 
Genotypes: w1118, Elav-Δtb-GFP (Elav-GAL4, TBPHΔ23/Δ23; uasGFP/+) and Elav-Δtb-GAD1 (Elav-
GAL4, TBPHΔ23/Δ23; uasGAD1/+). Quantification was done in GraphPad Prism 7.0, *p < 0.05, 
***p < 0.001 calculated by one-way ANOVA. Error bars SEM. Scale bar: 5 µm. n>200 boutons 
per genotype. 
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Fig. 26) Distribution of post-synaptic protein Disc Large in the NMJ of TBPH null larvae upon 
GAD1 overexpression in neurons. Disc Large was previously described to be downregulated 
in TBPH null flies. GAD1 reintroduction in neurons (Elav-Δtb-GAD1) rescued significantly (to 
wild type level) the distribution of Disc Large in comparison to the negative control (Elav-Δtb-
GFP). On the left: confocal microscopy acquisition of the motoneuron laying on the muscles 
6/7 of the second abdominal segment of third instar larvae. The nerve cell was stained with 
anti-HRP (green, merged to Dlg) and anti-Dlg (red). On the right: quantification of Dlg/Hrp 
intensity. Genotypes: w1118, Elav-Δtb-GFP (Elav-GAL4, TBPHΔ23/Δ23; uasGFP/+) and Elav-Δtb-
GAD1 (Elav-GAL4, TBPHΔ23/Δ23; uasGAD1/+). Quantification was done in GraphPad Prism 7.0, 
***p < 0.001 calculated by one-way ANOVA. Error bars SEM. Scale bar: 5 µm. n>200 boutons 
per genotype. 
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Fig. 27) Distribution of post-synaptic protein GluRIIA in the NMJ of TBPH null larvae upon 
GAD1 overexpression in neurons. GluRIIA was previously described to be downregulated in 
TBPH null flies. GAD1 reintroduction in neurons (Elav-Δtb-GAD1) rescued significantly (to 
wild type level) the distribution of GluRIIA in comparison to the negative control (Elav-Δtb-
GFP). On the left: confocal microscopy acquisition of the motoneuron laying on the muscles 
6/7 of the second abdominal segment of third instar larvae. The nerve cell was stained with 
anti-HRP (green, merged to GluRIIA) and anti-GluRIIA (red). On the right: quantification of 
GluRIIA/Hrp intensity. Genotypes: w1118, Elav-Δtb-GFP (Elav-GAL4, TBPHΔ23/Δ23; uasGFP/+) 
and Elav-Δtb-GAD1 (Elav-GAL4, TBPHΔ23/Δ23; uasGAD1/+). Quantification was done in 
GraphPad Prism 7.0, ***p < 0.001 calculated by one-way ANOVA. Error bars SEM. Scale bar: 
5 µm. n>200 boutons per genotype. 
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6.4) GAD1 silencing in neurons induces motility problems by 
regulating Disc Large and GluRIIA clustering 
We have previously suggested that GAD1 rescue of TBPH null motility 
problems was, most probably, related to the recovery of the distribution 
of pre-synaptic and post-synaptic proteins Syntaxin, Disc Large and 
GluRIIA. Still, we wanted to confirm that this recovery was specific to 
GAD1 metabolism. Thus, we silenced GAD1 in a TBPH+/+ background by 
using Elav-GAL4 and D42-GAL4. In this regard, we noticed strong 
locomotion impairments (Fig. 28) confirming the precious contribution 
of GAD1 to the control of locomotion behaviours in flies. Subsequently, 
we performed NMJ dissections in third instar larvae to investigate 
motoneurons morphological integrity. Thus, we did not find alterations 
in the neuronal growth upon GAD1 silencing (Fig. 29) indicating that 
GAD1 did not promote neuronal branching or the regular shape of the 
synaptic boutons, which was in agreement with our previous results. 
Finally, we stained the NMJs for Bruchpilot, our internal control, 
Syntaxin, Disc Large and GluRIIA. As expected, GAD1 silencing in Elav-
GAL4 affected the distribution of Disc Large (Fig. 32) and GluRIIA (Fig. 33). 
These results confirmed our hypothesis by which GAD1 promoted Disc 
Large and GluRIIA clustering. Syntaxin distribution, instead, was 
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unaltered (Fig. 31). We feel to speculate that Syntaxin was not directly 
influenced by GAD1 and that its recovery in our rescue experiments was 
due to a general beneficial status of the recovered system. Bruchpilot 
was not changing either (Fig. 30). Collectively these results suggested 
that GAD1 had an important role in TBPH null motility problems. It 
contributed to locomotion homeostasis and promoted the synaptic 
stability by regulating the clustering of Disc Large and GluRIIA at the post-
synaptic membrane.  
 
Fig. 28) Motility assays upon GAD1 silencing in pan-neuronal tissues. GAD1 suppression 
(GADi) with Elav-GAL4 and D42-GAL4 drivers induced strong motility problems in comparison 
to controls (ctrl). The phenotype was calculated by measuring the number of peristaltic 
movements third instar larvae were able to perform in 2 min. Genotypes: ctrl (on the left: 
uasLACZ/Elav-GAL4 and on the right: uasLACZ/+; +/D42-GAL4), GADi (on the left: Elav-
GAL4/+; uasGAD1-RNAi and on the right: D42-GAL4/uasGAD1-RNAi). Quantification was 
done in GraphPad Prism 7.0, ***p < 0.001 calculated by T-Test. Error bars SEM. Total n per 
genotype was 20.  
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Fig. 29) Branching of motoneurons upon GAD1 suppression in neurons. Silencing of GAD1 in 
neurons by Elav-GAL4 driver (Elav-GADi) did not affect the structural ramification of the 
motoneuron over the muscles. On the left: confocal microscopy acquisition of the 
motoneuron laying on the muscles 6/7 of the second abdominal segment of third instar 
larvae. On the right: quantification of synaptic branches ramification. The motoneuron was 
labelled anti-HRP. Genotypes: Elav-ctrl (uasLACZ/Elav-GAL4), Elav-GADi (Elav-GAL4/+; 
uasGAD1-RNAi). Quantification was done in GraphPad Prism 7.0, ns = non-significative, 
calculated by T-Test. Error bars SEM. Scale bar: 10 µm. Number of investigated larvae per 
genotype was 15.  
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Fig. 30) Bruchpilot distribution in the NMJ upon GAD1 silencing in neurons. GAD1 
suppression in neurons (Elav-GADi) did not influence Bruchpilot distribution in neurons. 
Bruchpilot was used as an internal control. On the left: confocal microscopy acquisition of 
the motoneuron laying on the muscles 6/7 of the second abdominal segment of third instar 
larvae. The nerve cell was stained with anti-HRP (green, merged to Brp) and anti-Brp (red). 
On the right: quantification of Brp/Hrp intensity. Genotypes: Elav-ctrl (uasLACZ/Elav-GAL4), 
Elav-GADi (Elav-GAL4/+; uasGAD1-RNAi). Quantification was done in GraphPad Prism 7.0, ns 
= non-significative, calculated by T-Test. Error bars SEM. Scale bar: 5 µm. Number of 
examined synaptic boutons per genotype was <200. 
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Fig. 31) Distribution of pre-synaptic protein Syntaxin in the NMJ upon GAD1 silencing in 
neurons. Syntaxin was not affected by GAD1 silencing in neurons (Elav-GADi). On the left: 
confocal microscopy acquisition of the motoneuron laying on the muscles 6/7 of the second 
abdominal segment of third instar larvae. The nerve cell was stained with anti-HRP (green, 
merged to Syx) and anti-Syx (red). On the right: quantification of Syx/Hrp intensity. 
Genotypes: Elav-ctrl (uasLACZ/Elav-GAL4), Elav-GADi (Elav-GAL4/+; uasGAD-RNAi). 
Quantification was done in GraphPad Prism 7.0, ns = non-significative, calculated by T-Test. 
Error bars SEM. Scale bar: 5 µm. Number of examined synaptic boutons per genotype was 
<200. 
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Fig. 32) Distribution of post-synaptic protein Disc Large in the NMJ upon GAD1 silencing in 
neurons. Disc Large was severely affected by GAD1 silencing in neurons (Elav-GADi) in 
comparison to the control (Elav-ctrl). On the left: confocal microscopy acquisition of the 
motoneuron laying on the muscles 6/7 of the second abdominal segment of third instar 
larvae. The nerve cell was stained with anti-HRP (green, merged to Dlg) and anti-Dlg (red). 
On the right: quantification of Dlg/Hrp intensity. Genotypes: Elav-ctrl (uasLACZ/Elav-GAL4), 
Elav-GADi (Elav-GAL4/+; uasGAD-RNAi). Quantification was done in GraphPad Prism 7.0, 
***p < 0.001 calculated by T-Test. Error bars SEM. Scale bar: 5 µm. Number of examined 
synaptic boutons per genotype was <200. 
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Fig. 33) Distribution of post-synaptic protein GluRIIA in the NMJ upon GAD1 silencing in 
neurons. GluRIIA was severely affected by GAD1 silencing in neurons (Elav-GADi) in 
comparison to the control (Elav-ctrl). On the left: confocal microscopy acquisition of the 
motoneuron laying on the muscles 6/7 of the second abdominal segment of third instar 
larvae. The nerve cell was stained with anti-HRP (green, merged to GluRIIA) and anti-GluRIIA 
(red). On the right: quantification of GluRIIA/Hrp intensity. Genotypes: Elav-ctrl 
(uasLACZ/Elav-GAL4), Elav-GADi (Elav-GAL4/+; uasGAD-RNAi). Quantification was done in 
GraphPad Prism 7.0, ***p < 0.001 calculated by T-Test. Error bars SEM. Scale bar: 5 µm. 
Number of examined synaptic boutons was per genotype <200. 
117 
 
7) The role of GAD1 in the glia 
7.1) GAD1 reintroduction in the glia rescues TBPH null motility 
defects and the clustering of GluRIIA at the post-synaptic 
membranes 
In the past we demonstrated that TBPH plays a strong role in glial 
homeostasis145. The silencing of TBPH in this tissue provoked strong 
motility problems and induced glial retractions, uncovering the neuronal 
terminals145. To investigate if GAD1 was involved in these processes, we 
reintroduced the enzyme in the glia using two glial drivers, Repo-GAL4 
and Gliotactin-GAL4. We observed that GAD1 reintroduction in the glia 
rescued the locomotion impairments of TBPH null third instar larvae (Fig. 
34) concluding that GAD1 had an important role in the glia.  
We then examined the NMJ. First, we investigated if the wrapping of the 
glia was ameliorating. The driver we utilized was Repo-GAL4 recombined 
to GFP to constitutively express GFP in the glia, enabling us to 
individualize these tissues around the motoneurons. We measured the 
area that the glia was occupying but no significant improvement in the 
glial wrapping was noticed upon GAD1 reintroduction. We then analysed 
if motoneuron integrity was modified. We measured neuronal branching 
and the shape of the synaptic boutons but none of these structures were 
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ameliorating upon GAD1 reintroduction (Fig. 35). As both glial wrapping 
and motoneurons branching depend strictly on the organization of 
microtubules, we feel to suggest that nor the glial GAD1 (or the neuronal 
GAD1, as seen in previous experiments) could replace TBPH functions 
related to the morphology organization of these tissues. Finally, we 
measured the clustering of Bruchpilot, Syntaxin, Disc Large and GluRIIA. 
Similarly as before, we labelled these markers in the NMJ of TBPH null 
third instar larvae and measured their distribution. We noticed that 
GAD1 reintroduction was rescuing the clustering of the GluRIIA (Fig. 39) 
but not modified Disc Large (Fig. 38) and Syntaxin (Fig. 37). Bruchpilot 
was used as internal control (Fig. 36). Here, glial GAD1 was able to 
recover GluRIIA clustering, suggesting a strong role of this enzyme in 
both neurons and glia regarding the synaptic communication 
homeostasis at the post-synaptic terminals. As Disc Large was not 
recovering this time, we speculate that glial GAD1 is less specific to Disc 
Large in comparison to its neuronal counterpart, although more 
elucidation will be required in this matter. We concluded that GAD1 
played an important role in the glia by controlling fly motility through the 
regulation of GluRIIA clustering at the post-synaptic membranes. 
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Fig. 34) GAD1 overexpression in the glia of TBPH null larvae. GAD1 reintroduction (Δtb-GAD1) 
in the glia by Repo-GAL4 and Gliotactin-GAL4 drivers have significantly recovered the motility 
defects of TBPH null third instar larvae compared to the negative control (Δtb-GFP). 
Performance was calculated as the number of peristaltic waves performed in 2 min by third 
instar larvae. Genotype: ctrl (on the left: TBPHΔ23/+; Repo-GFP, uasGFP/+ and on the right: 
TBPHΔ23, Gliotactin-GAL4/+; uasGFP/+), Δtb-GFP (on the left: TBPHΔ23/TBPHΔ23; Repo-GFP, 
uasGFP/+ and on the right: TBPHΔ23, Gliotactin-GAL4/TBPHΔ23; uasGFP/+), Δtb-GAD1 (on the 
left: TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/uasGAD1 and on the right: TBPHΔ23, Gliotactin-
GAL4/TBPHΔ23; uasGAD1/+). Quantification was done in GraphPad Prism 7.0, *p < 0.05, ***p 
< 0.001 calculated by one-way ANOVA. Error bars SEM. Total number of examined larvae per 
genotype was 25. 
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Fig. 35) Glial wrapping and motoneuron branching upon GAD1 overexpression in the glia of 
TBPH null larvae. Reintroduction of GAD1 in the glia (Repo-Δtb-GAD1) did not rescue glial 
wrapping and motoneuron branching in comparison to the negative control (Repo-Δtb-GFP). 
On the top: confocal microscopy acquisition of the motoneuron and supporting glia laying 
on the muscles 6/7 of the second abdominal segment of third instar larvae. The nerve cell 
was stained with anti-HRP (red) whereas the glia was labelled by a-GFP (green) that detects 
the constitutively expressing GFP under Repo driver. On the bottom: quantification of area 
covered by the glia over the motoneuron surface and quantification of the n. of branches of 
the motoneuron. Genotypes: Repo-ctrl (TBPHΔ23/+; Repo-GFP, uasGFP/+), Repo-Δtb-GFP 
(TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/+) and Repo-Δtb-GAD1 (TBPHΔ23/TBPHΔ23; Repo-GFP, 
uasGFP/uasGAD1). Quantification was done in GraphPad Prism 7.0, ns = ot significative, ***p 
< 0.001 calculated by one-way ANOVA. Error bars SEM. Scale bar: 10 µm. n>15 larvae per 
genotype. 
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Fig. 36) Distribution of pre-synaptic protein Bruchpilot in the NMJ of TBPH null larvae upon 
GAD1 overexpression in the glia. Bruchpilot was used as internal control. Our quantification 
shows that Bruchpilot distribution did not change in the tested samples. On the left: confocal 
microscopy acquisition of the motoneuron laying on the muscles 6/7 of the second 
abdominal segment of third instar larvae. The nerve cell was stained with anti-HRP (green, 
merged to Brp) and anti-Brp (red). On the right: quantification of Brp/Hrp intensity. 
Genotypes: Repo-ctrl (TBPHΔ23/+; Repo-GFP, uasGFP/+), Repo-Δtb-GFP (TBPHΔ23/TBPHΔ23; 
Repo-GFP, uasGFP/+) and Repo-Δtb-GAD1 (TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/uasGAD1). 
Quantification was done in GraphPad Prism 7.0, ns = not significative (not shown) calculated 
by one-way ANOVA. Error bars SEM. Scale bar: 5 µm. n>200 synaptic boutons per genotype. 
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Fig. 37) Distribution of pre-synaptic protein Syntaxin in the NMJ of TBPH null larvae upon 
GAD1 overexpression in the glia. GAD1 reintroduction in the glia (Repo-Δtb-GAD1) did not 
rescue the distribution of neuronal Syntaxin in comparison to the negative control (Repo-
Δtb-GFP). On the left: confocal microscopy acquisition of the motoneuron laying on the 
muscles 6/7 of the second abdominal segment of third instar larvae. The nerve cell was 
stained with anti-HRP (green, merged to Syx) and anti-Syx (red). On the right: quantification 
of Syx/Hrp intensity. Genotypes: Repo-ctrl (TBPHΔ23/+; Repo-GFP, uasGFP/+), Repo-Δtb-GFP 
(TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/+) and Repo-Δtb-GAD1 (TBPHΔ23/TBPHΔ23; Repo-GFP, 
uasGFP/uasGAD1). Quantification was done in GraphPad Prism 7.0, ns = not significative, 
***p < 0.001 calculated by one-way ANOVA. Error bars SEM. Scale bar: 5 µm. n>200 synaptic 
boutons per genotype. 
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Fig. 38).  Distribution of post-synaptic protein Disc Large in the NMJ of TBPH null larvae upon 
GAD1 overexpression in the glia. GAD1 reintroduction in the glia (Repo-Δtb-GAD1) did not 
rescue the distribution of neuronal Disc Large in comparison to the negative control (Repo-
Δtb-GFP). On the left: confocal microscopy acquisition of the motoneuron laying on the 
muscles 6/7 of the second abdominal segment of third instar larvae. The nerve cell was 
stained with anti-HRP (green, merged to Dlg) and anti-Dlg (red). On the right: quantification 
of Dlg/Hrp intensity. Genotypes: Repo-ctrl (TBPHΔ23/+; Repo-GFP, uasGFP/+), Repo-Δtb-GFP 
(TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/+) and Repo-Δtb-GAD1 (TBPHΔ23/TBPHΔ23; Repo-GFP, 
uasGFP/uasGAD1). Quantification was done in GraphPad Prism 7.0, ns = not significative, 
***p < 0.001 calculated by one-way ANOVA. Error bars SEM. Scale bar: 5 µm. n>200 synaptic 
boutons per genotype. 
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Fig. 39) Distribution of post-synaptic protein GluRIIA in the NMJ of TBPH null larvae upon 
GAD1 overexpression in the glia. GAD1 reintroduction in the glia (Repo-Δtb-GAD1) rescued 
(to wild type level) the distribution of neuronal GluRIIA in comparison to the negative control 
(Repo-Δtb-GFP). On the left: confocal microscopy acquisition of the motoneuron laying on 
the muscles 6/7 of the second abdominal segment of third instar larvae. The nerve cell was 
stained with anti-HRP (green, merged to GluRIIA) and anti-GluRIIA (red). On the right: 
quantification of GluRIIA/Hrp intensity. Genotypes: Repo-ctrl (TBPHΔ23/+; Repo-GFP, 
uasGFP/+), Repo-Δtb-GFP (TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/+) and Repo-Δtb-GAD1 
(TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/uasGAD1). Quantification was done in GraphPad Prism 
7.0, ***p < 0.001 calculated by one-way ANOVA. Error bars SEM. Scale bar: 5 µm. n>200 
synaptic boutons per genotype. 
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7.2) Glial GAD1 affects fly motility by regulating GluRIIA 
clustering at post-synaptic membrane 
In the previous experiment, GAD1 reintroduction in the glia rescued 
TBPH null motility defects and GluRIIA clustering indicating that the 
presence of this enzyme was important in neurons as well as in the glia. 
To confirm that these effects were GAD1 specific, we silenced GAD1 in 
the glial tissue using Repo-GAL4 as a driver. We noticed strong locomotor 
deficits in third instar larvae (Fig. 40).  
At the level of the NMJ, we noticed that motoneurons branching and 
synaptic bouton shape were not affected in third instar larvae (Fig. 41). 
This result was in agreement with our previous findings indicating that 
glial GAD1 did not promote morphological growth. Finally, we analysed 
the NMJ of third instar larvae for Bruchpilot, Syntaxin, Disc Large and 
GluRIIA distribution (Fig. 42-45). We noticed that GAD1 silencing in the 
glia strongly compromised GluRIIA clustering at the post-synaptic 
membranes. None of the other proteins were affected. These results 
suggested that GAD1 was specifically required in the glia to promote 
synaptic communication homeostasis by regulating GluRIIA distribution 
on the post-synaptic membranes. 
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Fig. 40) Larval locomotion upon GAD1 silencing in glial tissue. GAD1 suppression with Repo-
GAL4 driver (Repo-GADi) induced strong motility problems in comparison to the control 
(Repo-ctrl). The phenotype was calculated by measuring the number of peristaltic 
movements third instar larvae were able to perform in 2 min. Genotypes: Repo-ctrl 
(+/uasGFP; Repo-GAL4/+) and Repo-GADi (+/+; Repo-GAL4/uasGAD1 RNAi). Quantification 
was done in GraphPad Prism 7.0, ***p < 0.001 calculated by T-Test. Error bars SEM. n=20 
larvae per genotype. 
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Fig. 41) Motoneuron branching upon GAD1 silencing in the glia. Silencing of GAD1 in the glia 
by Repo-GAL4 driver (Repo-GADi) did not affect the structural ramification of the 
motoneuron over the muscles. On the left: confocal microscopy acquisition of the 
motoneuron laying on the muscles 6/7 of the second abdominal segment of third instar 
larvae. On the right: quantification of synaptic branches ramification. The motoneuron was 
labelled anti-HRP. Genotypes: Repo-ctrl (+/uasGFP; Repo-GAL4/+) and Repo-GADi (+/+; 
Repo-GAL4/uasGAD1 RNAi). Quantification was done in GraphPad Prism 7.0, ns = not 
significative, calculated by T-Test. Error bars SEM. Scale bar: 10 µm. n=15 larvae per 
genotype. 
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Fig. 42) Bruchpilot distribution in the NMJ upon GAD1 silencing in the glia. Bruchpilot was 
used as an internal control. Bruchpilot distribution did not change upon GAD1 silencing in 
the glia (Repo-GADi). On the left: confocal microscopy acquisition of the motoneuron laying 
on the muscles 6/7 of the second abdominal segment of third instar larvae. The nerve cell 
was stained with anti-HRP (green, merged to Brp) and anti-Brp (red). On the right: 
quantification of Brp/Hrp intensity. Genotypes: Repo-ctrl (+/uasGFP; Repo-GAL4/+) and 
Repo-GADi (+/+; Repo-GAL4/uasGAD1 RNAi). Quantification was done in GraphPad Prism 
7.0, ns = not significative, calculated by T-Test. Error bars SEM. Scale bar: 5 µm. Number of 
examined synaptic boutons per genotype was <200. 
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Fig. 43) Distribution of pre-synaptic protein Syntaxin in the NMJ upon GAD1 silencing in the 
glia. Syntaxin was downregulated in TBPH null flies. Glial GAD1 silencing (Repo-GADi) did not 
affect Syx distribution in the synapse. On the left: confocal microscopy acquisition of the 
motoneuron laying on the muscles 6/7 of the second abdominal segment of third instar 
larvae. The nerve cell was stained with anti-HRP (green, merged to Syx) and anti-Syx (red). 
On the right: quantification of Syx/Hrp intensity. Genotypes: Repo-ctrl (+/uasGFP; Repo-
GAL4/+) and Repo-GADi (+/+; Repo-GAL4/uasGAD1 RNAi). Quantification was done in 
GraphPad Prism 7.0, ns = not significative, calculated by T-Test. Error bars SEM. Scale bar: 5 
µm. Number of examined synaptic boutons per genotype was <200. 
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Fig. 44) Distribution of post-synaptic protein Disc Large in the NMJ upon GAD1 silencing in 
the glia. Glial GAD1 silencing (Repo-GADi) did not affect Disc Large distribution in the 
synapse. On the left: confocal microscopy acquisition of the motoneuron laying on the 
muscles 6/7 of the second abdominal segment of third instar larvae. The nerve cell was 
stained with anti-HRP (green, merged to Dlg) and anti-Dlg (red). On the right: quantification 
of Dlg/Hrp intensity. Genotypes: Repo-ctrl (+/uasGFP; Repo-GAL4/+) and Repo-GADi (+/+; 
Repo-GAL4/uasGAD1 RNAi). Quantification was done in GraphPad Prism 7.0, ns = not 
significative, calculated by T-Test. Error bars SEM. Scale bar: 5 µm. Number of examined 
synaptic boutons per genotype was <200. 
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Fig. 45) Distribution of post-synaptic protein GluRIIA in the NMJ upon GAD1 silencing in the 
glia. Glial GAD1 silencing (Repo-GADi) affected GluRIIA distribution on the post-synaptic 
membrane in comparison to the control (Repo-ctrl). On the left: confocal microscopy 
acquisition of the motoneuron laying on the muscles 6/7 of the second abdominal segment 
of third instar larvae. The nerve cell was stained with anti-HRP (green, merged to GluRIIA) 
and anti-GluRIIA (red). On the right: quantification of GluRIIA/Hrp intensity. Genotypes: 
Repo-ctrl (+/uasGFP; Repo-GAL4/+) and Repo-GADi (+/+; Repo-GAL4/uasGAD1 RNAi). 
Quantification was done in GraphPad Prism 7.0, ***p < 0.001 calculated by T-Test. Error bars 
SEM. Scale bar: 5 µm. Number of examined synaptic boutons per genotype was <200. 
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8) Role of GAD1 in neurotransmitter balance and 
neurodegeneration 
8.1) Glutamate concentration is high in the extracellular 
space of TBPH null flies 
Our findings indicated that GAD1 was downregulated in TBPH null flies 
and this modification provoked serious motility problems that were 
caused by alterations in the clustering of the proteins Disc Large and 
GluRIIA in the post-synaptic membranes. We discovered that GAD1 
influenced these proteins and GAD1 reintroduction in neurons or glia 
rescued Disc Large and GluRIIA distribution. Given that GAD1 cellular 
function is to convert Glutamate to GABA, as this enzyme was 
downregulated in TBPH mutants, we expected less enzymatic activity to 
convert one neurotransmitter into the other, with a consequent increase 
of Glutamate and decrease of GABA. Importantly, previous studies have 
shown that high Glutamate levels directly affect the sensitivity and 
distribution of the GluRIIA receptors causing excitotoxicity138. Therefore, 
to test the levels of Glutamate in TBPH mutant flies, we extracted the 
haemolymph of third instar larvae and performed a Liquid 
Chromatography followed by Mass Spectrometry (LC-MS) analysis. The 
results clearly indicated that there was an excess of Glutamate in TBPH 
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null flies in comparison to wild type (Fig. 46). Similar levels of Glutamate 
were observed when GAD1 was silenced in neurons (Elav-GADi). In 
addition, since our earlier experiments showed that GAD1 was required 
in both neurons and glia, we introduced for the first time a fly that allows 
the parallel overexpression of GAD1 in both tissues (Elav-Repo-Δtb-
GAD1) and compared it to GFP expression alone (Elav-Repo-Δtb-GFP), in 
both cases in a TBPH null background. We observed that Elav-Repo-Δtb-
GFP had similar Glutamate levels as TBPH null flies and that the parallel 
overexpression of GAD1 in neurons and glia was able to reduce 
Glutamate concentration to almost the wild type range. These results 
indicated that, due to the downregulation of GAD1 expression, TBPH null 
flies presented excessive levels of Glutamate in their extracellular space 
and suggested that the abundance of this neurotransmitter could cause 
excitotoxicity.  
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Fig. 46) Glutamate concentration in the haemolymph of TBPH null third instar larvae. We 
performed LC-MS to measure Glutamate concentration in the haemolymph of third instar 
larvae. Our results indicated excessive Glutamate levels in the haemolymph of TBPH null 
third instar larvae (TBPHΔ23/Δ23). Similar levels were obtained by GAD1 silencing in neurons 
(Elav-GADi). Glutamate concentration went down in our TBPH null GAD1 rescue experiments 
(Elav-Repo-Δtb-GAD1) in comparison to the negative control (Elav-Repo-Δtb-GFP). 
Genotypes: w1118, TBPHΔ23/Δ23, Elav-GADi (Elav/+; +/uasGAD1 RNAi), Elav-Repo-Δtb-GFP (Elav-
GAL4, TBPHΔ23/Δ23; Repo-GAL4/uasGFP), Elav-Repo-Δtb-GAD1 (Elav-GAL4, TBPHΔ23/Δ23; Repo-
GAL4/uasGAD1). Quantification was done by measuring the ratio between the chosen 
fragment of the fragmentation spectra of Glutamic acid and isotopic labelled Glutamic acid. 
Quantification was done in GraphPad Prism 7.0, *p < 0.05, ***p < 0.001 calculated by one-
way ANOVA. Error bars SEM. n=15-18 per genotype. Courtesy of Dr. Giulia Romano and Dr. 
Corrado Guarnaccia. 
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8.2) Treatment with GluRs inhibitors rescues motility 
problems in TBPH deficient flies  
In the previous experiment, we have shown that TBPH null flies suffered 
from an excess of Glutamate in their haemolymph. It is believed that this 
condition might be detrimental due to the increased stimulation of the 
GluRs, provoking over-firing and neuronal death. To test this hypothesis, 
we fed TBPH null larvae with different concentration of Memantine, a 
very specific GluRs antagonist and Lithium Chloride (LiCl), a less specific 
antagonist of GluRs. The drug was diluted in water and mixed with 
regular fly food. TBPH null flies were fed with the drug from 
embryogenesis till late larval stage, when the locomotion assays were 
performed. We found that 50 µM of Memantine was sufficient to 
partially rescue the motility problems observed in TBPH null larvae (Fig. 
47). Similar rescue was observed in TBPH null larvae treated with 5 mM 
of LiCl (Fig. 48). In addition, we observed that 50 µM of Memantine 
completely rescued the motility defects of TBPH-minus hypomorphic 
alleles generated after the silencing of the protein in neurons by RNAi 
(Fig. 49).  
136 
 
 
Fig. 47) Motility assays of TBPH null larvae after Memantine treatment. TBPH null third instar 
(TBPHΔ23/Δ23) larvae fed with 50 µM of Memantine (D) ameliorated locomotion performance 
in comparison to untreated animals (V), measured by the number of peristaltic movements 
performed in 2 min. Genotypes: w1118, TBPHΔ23/Δ23. V-vehicle, D-Drug. Quantification was 
done in GraphPad Prism 7.0, *p < 0.05, ***p < 0.001 calculated by one-way ANOVA. Error 
bars SEM. n=20 per genotype. 
 
Fig. 48) Motility assays of TBPH null third instar larvae after LiCl treatment. TBPH null larvae 
(TBPHΔ23/Δ23) fed with 5 mM of LiCl (D) ameliorated locomotion performance in comparison 
to untreated animals (V), measured by the number of peristaltic movements performed in 2 
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min. Genotypes: w1118, TBPHΔ23/Δ23. V-vehicle, D-Drug. Quantification was done in GraphPad 
Prism 7.0, *p < 0.05, ***p < 0.001 calculated by one-way ANOVA. Error bars SEM. n=20 per 
genotype. 
 
Fig. 49) Motility assay after Memantine treatment of larvae with reduced levels of TBPH 
expression in neurons. Third instar larvae expressing TBPH RNAi in neurons (Elav-TBi) and 
fed with 50 µM of Memantine (D) ameliorated locomotion performance in comparison to 
untreated animals (V), measured by the number of peristaltic movements performed in 2 
min. Genotypes: Elav-Ctrl (Elav-GAL4/uasGFP), Elav-TBi (Elav-GAL4/uasTBPH RNAi). 
Quantification was done in GraphPad Prism 7.0, ***p < 0.001 calculated by one-way ANOVA. 
Error bars SEM. V-vehicle, D-Drug. n=20 per genotype 
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8.3) Treatment with Memantine rescues completely the 
GluRIIA clustering defects described in larvae with reduced 
levels of TBPH expression in neurons 
We have discovered that the treatment with GluRs antagonist 
Memantine rescued the locomotion problems described in larvae with 
reduced levels of TBPH expression in neurons. We suggested that this 
rescue was due to the limitation in the binding excess of Glutamate to 
GluRs. Importantly, previous studies have shown that over-activation of 
GluRs was not only inducing excitotoxicity but, more interestingly, 
GluRIIA clustering downregulation138. Therefore, to test whether 
Memantine was able to revert this condition, we measured the levels of 
the GluRIIA in larvae with reduced levels of TBPH fed with Memantine 50 
µM (Fig. 50). We found that Memantine was able to completely rescue 
the clustering of GluRIIA at NMJ of larvae with reduced expression of 
TBPH in neurons, suggesting that Glutamate-GluRs over-activation was 
leading to GluRIIA clustering alterations.  
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Fig. 50) GluRIIA clustering of larvae with TBPH deficiency in neurons after Memantine 
treatment. Distribution of post-synaptic protein GluRIIA ameliorated in the NMJ of larvae 
with reduced levels of TBPH expression in neurons (Elav-TBi) after 50 µM treatment with 
Memantine (D) in comparison to untreated animals (V). On the left: confocal microscopy 
acquisition of the motoneuron laying on the muscles 6/7 of the second abdominal segment 
of third instar larvae. The nerve cell was stained with anti-HRP (green, merged to GluRIIA) 
and anti-GluRIIA (red). On the right: quantification of GluRIIA/Hrp intensity. Genotypes: Elav-
Ctrl (Elav-GAL4/uasGFP), Elav-TBi (Elav-GAL4/uasTBPH RNAi). V-vehicle, D-Drug. 
Quantification was done in GraphPad Prism 7.0, ***p < 0.001 calculated by one-way ANOVA. 
Error bars SEM. Scale Bar: 5 µm. n=20 per genotype 
 
8.4) GABA is strongly downregulated in TBPH null larval 
brains 
We demonstrated that TBPH null flies presented high levels of Glutamate 
and suggested that this alteration could be causing motility problems 
and neurodegeneration. However, the role of GABA, supposedly 
downregulated in TBPH mutant flies, was not specified. To test this 
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hypothesis, we stained with anti-GABA the NMJs and brains of TBPH null 
third instar larvae. GABA was barely detectable at Drosophila’s NMJs 
(Fig. 51) indicating that the flies may not require GABA for NMJ 
transmission. Next, we measured the levels of GABA in the brains of 
TBPH null third instar larvae. Here, we analysed the whole brain intensity 
ratio between GABA and Elav, a nuclear protein of neurons shown to be 
unaffected in TBPH mutants (data not shown). We discovered that TBPH 
null larval brains presented a strong reduction in the levels of GABA in 
comparison to wild type flies (Fig. 52). This finding supported our 
hypothesis and indicated that GABA downregulation could play an 
important role in TBPH null phenotypes.   
 
Fig. 51) GABA levels in Drosophila’s NMJ of TBPH null larvae. GABA was barely detectable at 
the level of NMJs of both wild type and TBPH null larvae. Confocal microscopy acquisition of 
the motoneuron laying on the muscles 6/7 of the second abdominal segment of third instar 
larvae. The nerve cell was stained with anti-HRP (red) and anti-GABA (green). Genotypes: 
w1118, TBPHΔ23/Δ23. Scale bar: 5 µm. Number of examined larvae per genotype was >20. 
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Fig. 52) GABA levels in Drosophila’s brain of TBPH null third instar larvae. GABA was strongly 
downregulated in the brains of TBPH null larvae (TBPHΔ23/Δ23) in comparison to wild type 
(w1118). On the left: confocal microscopy acquisition of third instar larval brains stained for 
anti-GABA (green), anti-Elav (red) and merged (Elav/GABA). On the right: Quantification of 
whole brain intensity GABA/Elav ratio. Genotypes: w1118, TBPHΔ23/Δ23. Quantification was 
done in GraphPad Prism 7.0, ns = not significative (not shown), ***p < 0.001 calculated by T-
Test. Error bars SEM. Scale bar: 50 µm. Number of examined brains per genotype was >10.  
 
8.5) Feeding of GABA does not rescue locomotion 
To test whether GABA downregulation had any involvement in TBPH 
mutants locomotion impairments, we fed TBPH null third instar larvae 
with different concentration of GABA, ranging from 20 mM to 200 mM 
(data shown only for 40 mM). No recovery of the locomotion 
impairments was observed in the treated animals (Fig. 53). Although this 
result could indicate that GABA may not be involved in TBPH null 
locomotion phenotypes, its role cannot be completely excluded. It is 
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possible that our feeding methodology was not efficient enough to test 
this hypothesis and more sensitive methodologies are necessary to reach 
definitive conclusions.  
 
Fig. 53) Motility assays of TBPH null larvae after GABA treatment. TBPH null third instar larvae 
(TBPHΔ23/Δ23) fed with 40 mM GABA (D) did not ameliorate in locomotion performance in 
comparison to untreated animals (V), measured by the number of peristaltic movements 
performed in 2 min. Genotypes: w1118, TBPHΔ23/Δ23. V-vehicle, D-Drug. Quantification was 
done in GraphPad Prism 7.0, ns = not significative, calculated by one-way ANOVA. Error bars 
SEM. n=20 per genotype. 
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9) GAD1 defects in humans and ALS patients 
9.1) TDP43-GAD1 relationships are conserved in humans 
The downregulation of GAD1 in TBPH null flies was a crucial event 
responsible for the synaptic alterations described in ALS fly models. To 
test if these regulatory defects were conserved through the evolution, 
we silenced TDP-43 in human neuroblastoma SK-N-BE cells and observed 
a strong downregulation of GAD67 (Fig. 54), the GAD1 homolog protein 
in humans, suggesting that these mechanisms were conserved in human 
tissues.  
 
Fig. 54) GAD67 expression values upon silencing of TDP-43 in human neuroblastoma cells. 
TDP-43 suppression induced GAD67 downregulation at protein level, measured by western 
blot analysis. Cells were transfected with TDP43 RNAi, lysed and prepared for western blot 
analysis (explained in detail in the Material and Methods section). Samples were run on 
polyacrylamide gels, transferred on nitrocellulose membranes and labelled with the 
appropriate primary antibodies. On the left: the membrane was labelled anti-TDP and anti-
144 
 
Tubulin. On the right: membrane was labelled anti-GAD67 and anti-GADPH. Beneath are the 
intensity quantification of Tubulin/TDP and GAPDH/GAD done in ImageJ. Courtesy of Dr. 
Raffaella Klima. 
 
9.2) GAD1 defects in ALS patients 
In the previous experiment, we have shown that TDP43-GAD1 
relationship was conserved through evolution suggesting that ALS 
patients could harbour similar defects in the regulation of the protein 
levels of GAD1. To test this hypothesis, we took advantage of iPSC lines 
reprogrammed from primary fibroblasts derived from ALS-patients 
carrying mutations in TDP-43 (patient #1 was carrying the mutation 
G287S, patient #2: G294V and patient #3: G378S)146. These cell lines were 
compared with lines derived from unaffected individuals (control #1 and 
control #2) in western blot analysis using anti-GAD67. We noticed that 
the protein levels of GAD67 were strongly reduced in all three ALS 
samples in comparison to controls (Fig. 55). Furthermore, we found that 
iPSC derived motoneurons (MNs) from patient #3 and control #1 
(differentiated in MNs following the protocol described in 147) showed 
similar defects in GAD67 expression at the protein and mRNA levels (Fig. 
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56 and 57) indicating that GAD1 misregulation was present in ALS 
patients and suggesting this enzyme could play an important role in ALS.  
 
Fig. 55) GAD67 protein expression in iPSC derived from ALS patients. GAD67 expression was 
downregulated in ALS patients in comparison to control # 1 and #2, measured by western 
blot analysis. iPSC were lysed and prepared for western blot analysis. Samples were run on 
polyacrylamide gel, transferred on nitrocellulose membrane and labelled with anti-GAD67 
and anti-GADPH. Beneath are the intensity quantification GAPDH/GAD done in ImageJ. 
Courtesy of Dr. Raffaella Klima. 
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Fig. 56) GAD67 protein expression in motoneurons derived from iPSC of ALS patient #3 in 
comparison to control #1. GAD67 protein was downregulated in motoneurons of ALS 
patients as measured by western blot analysis. iPSC were lysed and prepared for western 
blot (as explained in the Material and Methods section). Samples were run on polyacrylamide 
gel, transferred on nitrocellulose membrane and labelled with anti-GAD67 and anti-GADPH. 
Beneath are the intensity quantification GAPDH/GAD done in ImageJ. Courtesy of Dr. 
Raffaella Klima. 
 
Fig. 57) Expression of GAD67 mRNA in motoneurons derived from iPSC of ALS patient #3 in 
comparison to control #1. GAD67 mRNA was downregulated in motoneurons of ALS patients 
as measured by RT-PCR. Samples were prepared for RT-PCR analysis as explained in the 
Material and Methods section. Courtesy of Dr. Raffaella Klima. 
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DISCUSSION 
  
 
 
  
148 
 
10) TDP-43 influences GAD expression 
Thanks to wide genome proteomic analysis we found that GAD1, the 
enzyme that converts Glutamate to GABA, was translationally 
downregulated in flies lacking TBPH protein expression. These findings 
were later confirmed by western blot and RT-PCR, indicating that GAD1 
was both transcriptionally and translationally downregulated in TBPH 
null flies. As TBPH is a RNA binding protein, we suspected that TBPH was 
directly binding and regulating GAD1 mRNA. Thus, we performed 
immunoprecipitation studies (data not shown) but we did not see any 
binding interaction between the two molecules. As these experiments 
were done on the mature form of GAD1 mRNA, these results indicated 
that TBPH did not promote GAD1 mRNA transport or stability but left 
unanswered question about the steps that preceded, the transcription 
and processing of GAD1 pre-mRNA. Interestingly, our preliminary data 
(not shown) indicated that TBPH affects the stability of GAD1 pre-mRNA. 
However, we still do not know whether this regulation is performed at 
the pre-mRNA processing level (which is very likely given that TBPH is 
primarily a splicing factor) or if it is instead achieved by the assembly of 
the transcriptional machinery on the GAD1 promoter region, thus 
promoting the transcription of GAD1 gene.  
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11) GAD1 is required in both neurons and glia to maintain 
synaptic stability 
We have previously observed that several synaptic proteins, including 
the pre-synaptic protein Syntaxin and the post-synaptic proteins Disc 
Large and GluRIIA, were translationally downregulated and did not 
clusterize properly at synaptic terminals in TBPH null flies143. As GAD1 
was previously shown to regulate the clustering of the GluRIIA138, we 
reintroduced GAD1 gene by the UAS-GAL4 expression system, in both 
the neurons and the glia of TBPH null flies. We observed that GAD1 was 
required in both tissues to maintain the proper clustering of the GluRIIA. 
In addition, neuronal GAD1 was also promoting the clustering of Disc 
Large, the GluRIIA associated protein. For what concerned the 
metabolism of pre-synaptic proteins, we observed that in our rescue 
experiments the neuronal GAD1 was able to induce a weak recovery of 
Syntaxin. However, subsequent experiments did not confirm that the 
effect on Syntaxin was GAD1 specific. In addition, GAD1 was not able to 
rescue the morphology of pre-synaptic terminals, which was not 
surprising given that TBPH was shown to promote microtubule 
organization by directly regulating Futsch, the microtubule associated 
protein61, and many other proteins related to synapse structure and 
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function. To note, however, that the measurements related to the 
neuronal growth, the count of the number of branches and regular 
synaptic boutons in particular, were done manually and are appropriate 
only to detect gross changes in synaptic morphology: these 
measurements are way too simplistic and arbitrary to observe any subtle 
changes. The development of software able to count automatically these 
parameters would be of great help in the future. In absence of more 
sophisticated methods, our results indicated, all together, that although 
GAD1 could partially rescue the synaptic communication deficits in TBPH 
null flies, it was unable to compensate for the regulatory events TBPH is 
responsible for, especially the ones related to neuronal growth.  
 
12) GAD1 downregulation causes elevate levels of Glutamate 
and reduced levels of GABA 
Although we demonstrated that GAD1 promotes GluRIIA and Disc Large 
clustering, we could not explain the nature of this regulation. Many years 
back, Featherstone et al136, 138, suggested that high levels of Glutamate 
promoted the downregulation of GluRs field on post-syanptic 
membranes, a phenomenon associated with excitotoxicity prevention. 
Obviously, the downregulation of GAD1 would suggest such scenario. 
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Thus, we have found by LC-MS that the haemolymph of TBPH null larvae 
presented high levels of Glutamate. In addition, we observed that GAD1 
silencing in neurons could induce Glutamate levels that were equally 
high as those seen in TBPH mutants, indicating that this effect was GAD1 
specific. Finally, the simultaneous overexpression of GAD1 in both the 
neurons and glia in TBPH null larvae recovered Glutamate levels to wild 
type. However, it remains to be understood whether the silencing of 
GAD1 specifically in the glia would induce similar raises in Glutamate. As 
the glia is associated with Glutamate re-uptake from the synaptic cleft, 
glial GAD1 must have a fundamental role in excitotoxicity prevention. In 
contrast, the neuronal GAD (at least in humans) is primarily associated 
with the outer membranes of synaptic vesicles where it serves to convert 
Glutamate and pump GABA in. Interestingly though, as crucial proteins, 
such as Syntaxin, that relate to vesicle exocytosis are downregulated in 
TBPH mutants, Glutamate release in the synaptic cleft must be mediated 
by mechanisms that are not dependent of vesicular release. Indeed, 
Featherstone138 found that GluR field depended strictly on non-vesicular 
release of Glutamate. In this direction, we have seen that Memantine 
and LiCl, two widely recognized GluRs antagonists, ameliorated the 
locomotion phenotypes and rescued GluRIIA clustering in TBPH 
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deficiency larvae indicating that Glutamate-GluRs overstimulation 
leaded to synaptic instability. Regarding to that, it would be interesting 
to understand the effects that the binding excesses have on muscles and 
if this effects can, in some retroactive way, affect pre-synaptic 
homeostasis. Also, the increased binding of Glutamate to the pre-
synaptic GluRs should be experimented. 
Not surprisingly, we have found that GABA levels were compromised in 
TBPH null larval brains. The fruit fly seemed not to use GABA for NMJ 
transmission, so we could conclude that NMJ synaptic instability in TBPH 
null flies were primarily caused by Glutamate excess. However, as GABA 
is present at large concentrations in certain brain regions, where it acts 
as an inhibitory molecule for neuronal circuits, GABA downregulation 
could still play a fundamental role in TBPH null phenotype. We tried, 
unsuccessfully, to rescue TBPH null larvae by feeding them with different 
concentration of GABA. Nevertheless, we couldn’t be sure that GABA 
was able to get to the right regions of the brain after these treatments. 
More sensitive methodologies for GABA administration would allow 
definitive conclusions.  
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13) The TDP43-GAD1 relationship is conserved in humans and 
ALS patients may suffer from GAD67 downregulation 
GAD65 and GAD67, the human orthologs of GAD1, were previously 
found misregulated in AD, Parkinson and Huntington’s disease. In ALS, 
however, different observations were made regarding the role of this 
enzyme and its enzymatic products in relation to neurodegenerative 
processes. As we have demonstrated a strong link between Glutamate 
metabolism and TBPH in fruit flies, we questioned whether this 
relationship was conserved in humans. Thus, we silenced TDP-43 by RNAi 
in human neuroblastoma cells and observed a consequent 
downregulation of GAD67. More strikingly, we obtained iPSC derived 
from fibroblast of ALS patients harbouring mutations inside TDP-43 
protein and observed that these individuals were suffering from GAD67 
downregulation at both the protein and mRNA level. These findings were 
of crucial significance because they coupled, for the first time, two 
pathological mechanism, TDP-43 proteinopathy and Glutamate 
excitotoxicity, widely recognized in ALS disease and opened the path to 
the development of pharmaceutical compounds against a previously 
unexplored molecular target (GAD67). In this sense, the development of 
“drugs” able to stimulate GAD67 enzymatic activity would mimic the 
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effects seen in our genetic rescue experiments preventing excitoxicity 
and promoting synaptic stabilization.  
 
14) Future plans 
The lack of an appropriate antibody for GAD1 protein detection renders 
that study of the function and regulation of this gene troublesome. Our 
previous biochemical studies were done on GAD1MIMIC, that is the 
endogenous gene that has the mimic cassette (EGFP-FlAsH-StrepII-TEV-
3xFlag-tag) inserted in the middle of the coding sequence of the protein. 
However, this methodology has some drawbacks: first, we believe that 
the position of the insert disturbs the proper folding, thus regulation and 
function of the protein. In this sense, we performed 
immunohistochemistry using an anti-EGFP to study the localization of 
the protein and whether it changed in TBPH null flies and noticed that 
GAD1 was not co-localizing with GABA expressing cells in the brain (data 
not shown), which was strange given the function of this protein. In 
addition, as the enzyme must dimerize to be activated, the mutated form 
of the protein might also disturb the functional, non-mutated, copy. 
Moreover, as the enzyme is downregulated in TBPH null flies, it was 
unfavourable to perform additional studies in this genetic background. 
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In this respect, we decided to clone a gene that would harbour tags on 
both the N-terminal and C-terminal of the protein and be under UAS 
control. This construct could help us understand more about GAD1 
metabolism. We will study GAD1 protein stability, localization and 
interactome. For instance, despite its very likely that TBPH regulates 
GAD1 pre-mRNA, GAD1 protein downregulation could initially be 
triggered by other cellular or environmental factors and, as this would 
result in Glutamate excitoxicity and stress, it could be the first trigger to 
TBPH downregulation, eventually leading to further problems in GAD1 
expression in a feedback mechanism. Secondary, this construct could 
allow us to find ways (either drugs or induced post-translational changes) 
that would boost the natural function of the GAD1 enzyme, as this would 
mimic our rescue experiments. However, since the cloned gene would 
be under UAS control, we will not be able to determine which cells 
naturally express the protein and to what extent. For this purpose, it will 
be required to insert a tag at the end of the endogenous gene. This can 
be done, nowadays, with Crispr/CAS9 technology. Otherwise an antibody 
that detects the endogenous protein can be made, but this approach can 
be more costly and troublesome.  
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Concluding remarks 
ALS is a devastating disease of the motor system. Poor diagnosis and 
treatment are consequent to the little understanding of the 
pathogenesis. For a long time, Glutamate metabolism disorders have 
been linked to disease onset and progression. Glutamate levels are high 
in ALS patients, which is believed to cause excitotoxicity. Another 
important contributor to ALS is TDP-43, a nuclear and RNA binding 
protein that is found cytosolically aggregated and post-translationally 
modified in the great majority of the patients.   
In this PhD thesis we have demonstrated a link between TDP-43 and 
Glutamate metabolism. Thanks to wide screen proteomic analysis, we 
found that TBPH null flies had downregulated levels of GAD1. This in turn 
caused an excess of Glutamate and lack of GABA, promoting 
excitotoxicity, downregulation of GluRs and the GluR-associated 
proteins. Importantly, we observed that TDP43-GAD1 relationship was 
conserved in humans and that ALS patients carrying mutations in TDP-43 
presented defects in GAD67 gene expression.   
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MATERIAL AND METHODS 
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Fly strains 
The following genotypes were used: 
w[1118], w[1118];TBPHΔ23/CyO-GFP, w[1118];TBPHΔ142/CyO-GFP, 
w[1118];Elav-GAL4/CyO-GFP, w[1118];D42-GAL4/D42-GAL4, 
w[1118];Repo-GAL4/TM3Sb, w[1118];Gliotactin-GAL4/CyO-GFP, 
w[1118];GMR-GAL4/GMR-GAL4,       w[1118];UAS-GFP(mCD8), 
w[1118];UAS-TBPH/UAS-TBPH, w[1118];Mi[MIC]GAD1MI09277/TM3Sb, 
UAS-GAD1/TM3Sb, UAS-GAD1 RNAi (#28079)/Tm3Sb, UAS-TBPH RNAi 
(#ID38377, VDRC), UAS-LacZ/CyO. 
 
Fly genotypes used in figures 
Fig. 18-19, 21) 
- w1118 
- TBPHΔ23/Δ23  
- TBPHΔ142/ Δ142  
 
Fig. 20) 
- w1118 
- TBPH+/+; GAD1MIMIC/GAD1  
- TBPHΔ23/Δ23; GAD1MIMIC/GAD1 
Fig. 22) 
- w1118 
- Elav-GAL4, TBPHΔ23/Δ23; uasGFP/+ 
- Elav-GAL4, TBPHΔ23/Δ23; uasGAD1/+ 
- Elav-GAL4, TBPHΔ23/Δ23; uasTBPH/+ 
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- w1118 
- TBPHΔ23/Δ23; uasGFP/D42-GAL4 
- TBPHΔ23/Δ23; uasGAD1/D42-GAL4 
- TBPHΔ23/Δ23; uasTBPH/D42-GAL4 
Fig. 23-27) 
- w1118 
- Elav-GAL4, TBPHΔ23/Δ23; uasGFP/+ 
- Elav-GAL4, TBPHΔ23/Δ23; uasGAD1/+ 
Fig. 28) 
- uasLACZ/Elav-GAL4 
- Elav-GAL4/+; uasGAD1-RNAi 
- uasLACZ/+; +/D42-GAL4 
- D42-GAL4/uasGAD1-RNAi 
Fig. 29-33) 
- uasLACZ/Elav-GAL4 
- Elav-GAL4/+; uasGAD1-RNAi 
Fig. 34) 
- TBPHΔ23/+; Repo-GFP, uasGFP/+ 
- TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/+ 
- TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/uasGAD1 
- TBPHΔ23, Gliotactin-GAL4/+; uasGFP/+ 
- TBPHΔ23, Gliotactin-GAL4/TBPHΔ23; uasGFP/+ 
- TBPHΔ23, Gliotactin-GAL4/TBPHΔ23; uasGAD1/+ 
Fig. 35-39) 
- TBPHΔ23/+; Repo-GFP, uasGFP/+ 
- TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/+ 
- TBPHΔ23/TBPHΔ23; Repo-GFP, uasGFP/uasGAD1 
Fig. 40-45) 
- +/uasGFP; Repo-GAL4/+ 
- +/+; Repo-GAL4/uasGAD1 RNAi 
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Fig. 46) 
- w1118 
- TBPHΔ23/Δ23  
- Elav-GAL4/+; uasGAD1-RNAi 
- Elav-GAL4, TBPHΔ23/Δ23; Repo-GAL4/uasGFP 
- Elav-GAL4, TBPHΔ23/Δ23; Repo-GAL4/uasGAD1 
Fig. 47-48) 
- w1118 + Vehicle 
- w1118 + Drug 
- TBPHΔ23/Δ23 + Vehicle 
- TBPHΔ23/Δ23 + Drug 
Fig. 49-50) 
- Elav-GAL4/uasGFP + Vehicle 
- Elav-GAL4/uasTBPH RNAi + Vehicle 
- Elav-GAL4/uasTBPH RNAi + Drug 
Fig. 51-53) 
- w1118 
- TBPHΔ23/Δ23  
 
 
Protein separation by two-dimensional gel (IEF/SDS PAGE) and analysis 
by mass spectrometry 
Three independent protein extracts from fly heads were prepared for the 
two TBPH null mutants and the wild type strain. After Bradford 
quantification equal protein amounts were precipitated by TCA, and 
further solubilized in iso-electro-focusing (IEF) rehydration solution with 
0.6% IPG buffer pH 3-11 NL (from GE Healthcare Bio-sciences AB). The 
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extracts were then subjected to isoelectrofocusing with nonlinear 
immobilized pH-gradient strips (pH3-11 NL), 13 cm in lenght. The 
isoelectrofocusing was programmed at: 4 h at 50V, 1 h at 500V, 2 h at 
1000V up to h x 48000V. After equilibration of the focused strips in 6 M 
urea, 30% glycerol, 50 mM Tris-HCL (pH 8.8), 2% SDS, 62.5 mg 
iodoacetamide and bromophenol blue, strips were subjected to 
electrophoretic separation on a 14% SDS polyacrylamide gels (of the 
following dimensions: 18 x 20 x 0.15 cm) run overnight at 12 mA. After 
run, gels were fixed (1hr 10%(v/v) ethanol-7% (v/v) acetic acid) and 
stained with 0.12% Colloidal G-250 Coomassie Blue before acquisition of 
spot intensity (300 dpi-linear response conditions) with an Epson 
Expression 1680 Pro Scanner. pI values were calculated according to the 
pH curve of the pH gradient strips that the supplier provided (GE life 
Sciences), whereas molecular masses of proteins were determined 
according to semi-logarithmic curves of log10 molecular mass versus 
migration distance. Image acquisition was done for all nine gels (analysis 
done in triplicate for any strain) and analysed with Redfin 3 program 
(Ludesi AB, Lund, Sweden) that includes all to all spot matching and 
normalization according to total protein content. If the difference of the 
mean spot intensity was greater than 1.5-fold between the groups (p < 
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0.05), the protein was considered differentially expressed and were 
excised from gel and sent to mass spectrometry analysis performed by 
Proteome Factory AG in Germany for nano LC-ESI-MS/MS analysis. 
 
Western blot analysis 
Third instar larval brains, or S2 cells, were lysed in lysis buffer (10mM 
Tris, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 10% Glycerol, 50 mM NaF, 
5 mM DTT, 4 M Urea, pH 7.4, protease inhibitors (Roche, 
#11836170001)) and after protein quantification of lysates by Qubit 
(Q#33211, Invitrogen), samples were separated on 10% SDS-PAGE and 
transfer to 0,22um nitrocellulose membranes (#NBA083C Whatman 
Protran). Membrane were blocked in 5% non-fat dry milk in Tris Buffered 
Saline + 0.1 % Tween 20 (TBS-T).  
SK-N-BE and iPSC were resuspended in ice cold PBS + Protease Inhibitors, 
followed by sonification (Biorupture, Diagenode).  
Primary antibodies were used with the following concentration: anti-Flag 
M5 (1:10000, Sigma F4042), anti-cMyc (1:3000, Santa Cruz 9E10), anti-
HA (1:6000, Cell Signalling, 6E2), anti-tubulin DM1A (1:4000, Calbiochem 
#CP06), anti-GADPH (1:2000, Santa Cruz 47724 SC), anti-GAD1 (#5305 
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Cell Signaling 1:2,000). Secondary antibodies concentration: anti-rabbit 
HRP conjugated (1:10000, Pierce #32460), anti-mouse HRP conjugated 
(1:10000, Pierce # 32430). For detection, SuperSignal West Femto 
Maximum Sensitivity Substrate Kit (Pierce, #PR34095) was used. 
Quantification was performed by ImageJ after acquisition of the 
autoradiographic films with an Epson Expression 1680 Pro Scanner. 
 
RT-PCR 
RNA of third instar larval brains and of IPS derived motoneurons were 
extracted with RNeasy Microarray MiniKit (Qiagen, #73304) plus 
QIAshredder (Qiagen, #79654), and after DNase treatment (Promega, 
#M6101) were retro-transcribed with oligo-dT and SuperScript III First-
Strand Synthesis (TermoFischer, #18080051). Primers were specifically 
designed for the Gad1 gene of drosophila and human origin, while as 
housekeeping we select a set of primers for RpL11 and GAPDH for 
drosophila and human respectively: 
GAD1: 5′GAATTCAGAGCATAGAAGCCACCG3′ and 
5′CAACTGGCTCTTCATCTTCTCCTG3′ 
Rpl11: 5′CCATCGGTATCTATGGTCTGGA3′ and 5′CATCGTATTTCTGCTGGAACCA3′ 
Gapdh: 5′CTGGGCTACACTGAGCACC3′ and 5′AAGTGGTCGTTGAGGGCAATG3′ 
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GAD67: 5′CCTCAACTATGTCCGCAAGAC3′ and 5′TGTGCGAACCCCATACTTCAA3′ 
The samples were quantified according to the ΔΔCT equation and 
normalized on the genotype of control.  
 
Larval movement 
Larvae at 3rd instar stage (120h old) were carefully picked from fly vials, 
washed in a drop of water, selected against GFP balancer under UV lamp 
and collected into 0.6% agar plates. One larva at the time was picked, 
transferred to 10 cm diameter agar plate, and after a period of 
adaptation of 30 s, the number of peristaltic waves were counted for a 
period of 120 s. To confirm the right genotype of the selected and tested 
larvae, after crawling they were transferred to a fresh food vial, for 
pupae metamorphosis and enclosure into adult fly. Approximately 20 
larvae per genotype were tested.  
 
Larval NMJ immunohistochemistry 
Larvae at 3rd instar stage were selected against GFP balancer under the 
UV lamp and kept in small 0.6% agar plates as described earlier. Larvae 
were then picked up individually, dissected on sylgard plates in HL-3149, 
165 
 
and fixed for 20 min in 4% formaldehyde (for anti-GluRIIA larvae were 
fixed 5 min in methanol at -20ᵒC). After formaldehyde fixation, larvae 
were transferred in 0,5 ml tubes and kept in HL-3 buffer in ice. After the 
dissection was over for all genotypes, dissected larvae were washed 15 
min (3 x 5 min) in PBST (0.1% Tween 20 in Phosphate Buffer Saline), and 
a blocking step of 30 min in 5% Normal Goat Serum (NGS) in PBST (NGS-
PBST) preceded the overnight incubation at 4ᵒC with primary antibodies 
in 5% NGS-PBST. Primary antibodies were removed by 30 min (3 x 10 
min) washes in PBST, and a second blocking step of 5% NGS-PBST of 30 
min was performed before the incubation with the secondary antibodies 
that last 2h at room temperature. After a 1h wash (3 x 20 min) in PBST, 
samples were incubated overnight at 4ᵒC in 30 µl of the mounting 
medium Slow Fade (S36936 Thermofisher). The next day, for mounting, 
larvae were transferred to the microscope slide, brain and gut were 
removed, and larvae were properly positioned, overlaid with Slow Fade, 
closed with a coverslip and sealed with nail polish. The microscope slides 
stored at 4ᵒC were acquired on confocal microscope.  Primary antibodies 
concentration: anti-Syx 8C3s (1:15, DSBH), anti-BRP (1:50, DSHB), anti-
DLG 4F3c (1:250, DSHB), anti-GluRIIA 8B4D2c (1:15, DSHB), anti-GFP 
(1:200, Life Technologies), anti-HRP (1:150, Jackson). Secondary 
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antibodies concentration: Alexa Fluor 488 (1:500, rabbit and mouse, Life 
Technologies), Alexa Fluor 555 (555, rabbit, mouse, rat, Life 
Technologies). 
 
Larval brain immunohistochemistry 
Larvae, selected as previously described, were put in a drop of PB, where 
brains were extracted to be subsequently transferred in 0,5 ml tubes 
containing 4% formaldehyde in PBT (0.3% Triton X100 in Phosphate 
Buffer) in ice. After all brains were extracted, samples were removed 
form ice and fixed for 20 min at room temperature. After a wash of 60 
min (3 x 20 min), brains were subjected to a blocking step of 30 min in 
5% NGS-PBT before an overnight incubation at 4ᵒC, with primary 
antibodies diluted in 5% NGS-PBT. The day after, a washing step of 60 
min (3 x 20 min) precede an incubation with secondary antibodies in 5% 
NGS-PBT for 2h at RT. Three further washing steps in PBT, 20 min each, 
were performed before the overnight incubation with the mounting 
media Slow Fade at 4ᵒC. The day after, brains were mounted on 
microscope slide. Primary antibodies concentration: anti-GABA (1:500, 
Sigma), anti-Elav (1:250, DSHB). Secondary antibodies concentration: 
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Alexa Fluor 488 (1:500, rabbit, Life Technologies), Alexa Fluor 555 (555, 
rat, Life Technologies). 
 
Image acquisition and quantification 
The images were acquired using a 63x oil lens on a Zeiss 510 Meta 
confocal microscope and processed with the Zeiss LSM software. 
Microscope and computer settings were maintained equal for all 
acquired larvae. Images of whole motoneurons laying on muscles 6 and 
7 of the second abdominal segment were taken with a 2-fold 
magnification and analysed with ImageJ. For the quantification of pre- 
and post-synaptic proteins all samples were always labelled with both an 
anti-HRP and with the antibody against the protein of interest and the 
ratio between the mean intensity of their respective signals was 
measured for each synaptic bouton in the motoneuron’s terminal. Glial 
area quantification was done by measuring the area that glia was 
occupying versus the area of the presynaptic terminal. Quantification of 
the number of branches was done at 0.7-fold magnification counting the 
number of motoneuron’s extensions from the main branch. The 
regularity of synaptic boutons was calculated by measuring the number 
of big synaptic boutons with spherical shape. All statistical analysis was 
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performed with GraphPad Prism 7.0 applying Unpaired Student’s T-Test 
or three-way ANOVA test (Bonferroni post-test). 
 
Drug feeding 
All drugs tested, were dissolved in melted regular fly food at the proper 
final concentration (stocks: Memantine 4.6 mM, Lithium Chloride 1 M 
and GABA 8 M). Parental flies were kept in drug-added-food for a period 
of time of 24h and were subsequently discarded. The embryos, laid in 
that period of time, were allowed to reach the third instar stage before 
performing larval movements assays. 
 
Extraction of larval haemolymph 
Haemolymph was extracted from 15-18 larvae at third instar stage for a 
total volume of 2 µl per genotype in the following manner: third instar 
larvae were pinned at the extremities and inserted in 0.5 ml tube that 
was cut on the bottom with a 3 mm incision, inserted in a 1.5 ml tube 
and centrifuged at top speed for 20 seconds approximately. The 
haemolymph extracted was stored at – 80 ᵒC for further analysis. 4 µl of 
the haemolymph extract, were mixed with 200 µl of internal standard 
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solutions (10µM of L-Glutamic acid-2,3,3,4,4-d5 from Merck KGaA, 
Germany) in acetonitrile : water (60 : 40) with 10 mM of NH4OAc. After a 
centrifugation step, 5 µl of sample solution was run into LC-MS/MS. 
 
Gradient elution profile and instrument 
Two mobile phases, A and B, were constituted of 0.1% of formic acid in 
water and 0.1% of formic acid in acetonitrile respectively. The profile of 
gradient elution was the following: 0 min for 10% A, 3 min for 10% A, 13 
min for 100% A, 20 min for 100% A, 21 min for 10% A, 31 min for 10% A. 
The HPLC instrument used was the Gilson 234 autosampler (from Gilson 
Inc., Middleton, WI), 306 Binary Pump and a Thermostatted 
Compartment Column (from Agilent Technologies, Morges, Switzerland). 
The retention of the chromatography was obtained with a hydrophilic 
liquid chromatography interaction (HILIC) column (ZIC®-HILIC, 150 × 2.1 
mm i.d., 3.5μm, from Merck KGaA, Germany), run at 250 µl/min at 30 ᵒ C. 
The detection of eluates was done by amaZonSL ion trap MS (from 
Bruker Daltonik GmbH, Germany) in the positive electrospray ionization 
(ESI) mode. The voltage of the ion spray was set at 4500 V with a source 
temperature of 200 ᵒC. Data were acquired according to m/z 148.1/84.1 
transition of L-Glutamate and 153.1/89.1 transition of d5-L-Glutamate 
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(internal standard), followed by Compass Data Analysis 4.2 analysis 
(Bruker). 
 
Cellular cultures and RNAi silencing  
Standard conditions in DMEM-Glutamax (ThermoFisher Scientific, 
#31966-021) with the addition of 10% fetal bovine serum and 1X 
antibiotic-antimycotic solution (Sigma, #A5955) were used for SK-N-BE 
neuroblastoma cell culturing. TDP-43 silencing was done with HiPerfect 
Transfection Reagent following manufacturer instructions (Qiagen, 
#301705). The RNA interference sequences were the following: siRNA 
specific for human TDP-43 - (5′-gcaaagccaagaugagccu-3′); siRNA specific 
for Luciferase (Sigma, 5′-uaaggcuaugaagagauac-3′). Before transfection, 
2-4 x 105 cells per well, in a total volume of 1.4 ml of medium containing 
10% fetal serum were seeded in a 6-well plate. 3 µl of each siRNA (stock 
40 µM in water), was diluted in 91 µl of Opti-MEM1 (ThermoFisher, # 
51985-026), after a 5 min incubation at RT, 6 µl of HiPerfect Transfection 
Reagent were added, incubation of 10 minutes was done to allow 
formation of the complexes and finally the mixture was drop-wise added 
to cells. Silencing procedure was repeated after 24h and 48h.  
171 
 
iPS cell cultures and differentiation to MN 
Dermal biopsies were used to obtain fibroblasts from ALS patients 
(patient # 1 was carrying G287S mutation, patient # 2: G294V mutation 
and patient # 3: G378S; all mutations were inside TDP-43 gene, as 
schematically shown in the figure 58, found below) and unaffected 
individuals (control # 1 and #2) which were reprogrammed in iPS cell by 
CytoTune iPS 2.0 Sendai Reprogramming Kit (Life Technologies)146, based 
on the Sendai virus (SeV) vectors in addition to OCT4, SOX2, c-Myc an 
KLF4, the four reprogramming factors cloned inside the virus. iPSCs with 
an embryonic stem cell (ESC) like morphology were cultured on Matrigel-
coated dishes (BD Biosciences) inside Essential E8 media (Life 
Technologies) and maintained at 37ᵒC with 5% CO2. iPS cells 
differentiation in MNs was done as described in 147.  
All studies that involved human samples were performed in accordance 
with the Code of Ethics of the World Medical Association (Helsinki 
Declaration) and in compliance with national legislations and 
institutional guidelines. Dermal biopsies (Eurobiobank) were consented 
by the ethical committee of the IRCCS Foundation Ca’ Grande Ospedale 
Maggiore Policlinico).  
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Fig. 58) Schematic representation of the positions of TDP-43 mutations, derived from ALS 
patient #1, #2 and #3, used in figures 55, 56 and 57. Detailed explanation in the text.   
 
Statistical analysis 
All data analysis was done with GraphPad Prism 7.0. 
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